pharmaceutics
Article
Development and Quality Control of a Population
Pharmacokinetic Model Library for Caspofungin
NuoXu1,2,† ,YufeiShi1,2,† ,YixueWang3,WenyaoMak1 ,WenyuYang1 ,KarWengNg4 ,YueWu5,
ZhijiaTang1 ,QingfengHe1,2 ,GangfengYan3,XiaoqiangXiang1,* andXiaoZhu1,2,*
1 DepartmentofClinicalPharmacyandPharmacyAdministration,SchoolofPharmacy,FudanUniversity,
Shanghai201203,China;22211030092@m.fudan.edu.cn(N.X.);yufei_shi@fudan.edu.cn(Y.S.);
makwenyao@gmail.com(W.M.);21211030109@m.fudan.edu.cn(W.Y.);zjtang@fudan.edu.cn(Z.T.);
qf_he@fudan.edu.cn(Q.H.)
2 HunanKeyLaboratoryforBioanalysisofComplexMatrixSamples,Changsha410000,China
3 DepartmentofCriticalCareMedicine,Children’sHospitalofFudanUniversity,NationalChildren’sMedical
Center,Shanghai200000,China;yixuewang08@aliyun.com(Y.W.);gangfeng_yan@fudan.edu.cn(G.Y.)
4 DepartmentofPharmacotherapyServices,HospitalKualaLumpur,MinistryofHealth,KualaLumpur50586,
Malaysia;nkweng@moh.gov.my
5 DepartmentofClinicalPharmacy,ShenzhenChildren’sHospital,MedicalCollege,ShantouUniversity,
Shenzhen518000,China;wuyue161@163.com
* Correspondence:xiangxq@fudan.edu.cn(X.X.);xiaozhu@fudan.edu.cn(X.Z.);Tel.:+86-21-51980024(X.X.);
+86-21-51980024(X.Z.)
† Theseauthorscontributedequallytothiswork.
Abstract:Background:Caspofunginisanechinocandinantifungalagentcommonlyusedasthefirst-
linetherapyforinvasivecandidiasis,salvagetherapyforinvasiveaspergillosis,andempiricaltherapy
forpresumedfungalinfections.Pharmacokinetic(PK)variabilitiesandsuboptimalexposurehave
beenreportedforcaspofungin,increasingtheriskofinsufficientefficacy.Objective:Thisworkaimed
todevelopacaspofunginpopulationpharmacokinetic(popPK)libraryanddemonstrateitsutility
Citation:Xu,N.;Shi,Y.;Wang,Y.; byassessingtheprobabilityoftargetattainmentacrossdiversesettings.Methods:Weestablisheda
Mak,W.;Yang,W.;Ng,K.W.;Wu,Y.; caspofunginpopPKmodellibraryfollowingarigorousliteraturereview,re-implementingselected
Tang,Z.;He,Q.;Yan,G.;etal. modelsinRwithrxode2.Qualitycontrolproceduresincludedacomparisonofdifferentstudiesand
DevelopmentandQualityControlof assessingcovariateimpacts.ModellibrarieswereprimarilyusedtoperformMonteCarlosimulations
aPopulationPharmacokineticModel toestimatetargetattainmentandguidepersonalizeddosinginCandidainfections.Results:Atotal
LibraryforCaspofungin.
of13models,one-ortwo-compartmentmodels,wereincluded.Themostsignificantcovariateswere
Pharmaceutics2024,16,819.
bodysize(weightandbodysurfacearea),liverfunction,andalbuminlevel.Theresultsshowthat
https://doi.org/10.3390/
childrenandadultsshowedconsiderabledifferencesinpharmacokinetics. ForC.albicansandC.
pharmaceutics16060819
parapsilosis,noneofthepopulationsachievedaPTAof≥90%attheirrespectivesusceptibleMIC
AcademicEditors:AntonelloDi values.Incontrast,forC.glabrata,70%oftheadultstudiesreachedaPTAof≥90%,whileallpediatric
Paolo,KatarinaVucˇic´evic´and studies achieved the same PTA level. Conclusion: At the recommended dosage, adult patients
BranislavaMiljkovic´
showednotablylowerexposuretocaspofungincomparedtopediatricpatients.Consideringbody
Received:6May2024 size,liverfunction,andserumalbuminiscrucialwhendeterminingcaspofungindosageregimens.
Revised:30May2024 Furthermore,furtherresearchisrequiredtocomprehensivelyunderstandthepharmacokineticsof
Accepted:5June2024 caspofungininpediatricpatients.
Published:17June2024
Keywords:caspofungin;individualizeddosing;populationpharmacokinetics;modellibrary
Copyright: © 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
1. Introduction
Thisarticleisanopenaccessarticle
Echinocandins,includingcaspofungin,micafungin,andanidulafungin,representa
distributed under the terms and
breakthroughinantifungaltreatment. Caspofunginblocksthesynthesisofanessential
conditionsoftheCreativeCommons
Attribution(CCBY)license(https://
fungalcellwallcomponent,β-(1,3)-D-glucan,leadingtotheosmoticinstabilityandlysis
creativecommons.org/licenses/by/ ofthefungalcell. Duetoitsselectiveactiononfungalcells,caspofunginisusuallywell
4.0/). tolerated without common significant side effects. Caspofungin exerts potent activity
Pharmaceutics2024,16,819.https://doi.org/10.3390/pharmaceutics16060819 https://www.mdpi.com/journal/pharmaceutics
Pharmaceutics2024,16,819 2of23
againstCandidaandAspergillusspp.,servingasthefirst-linetherapyforinvasivefungal
infections(IFIs), salvagetherapyforinvasiveaspergillosis, andempiricaltreatmentfor
presumedfungalinfectionsinchildrenoverthreemonthsandinadults[1,2].
With poor oral bioavailability (<0.2%), caspofungin can only be administered by
slow intravenous infusion over approximately one hour. About 97% of caspofungin
bindstoplasmaproteinsafterenteringthebloodstream. Followinginfusion,theplasma
concentrationofcaspofungindeclinesinapolyphasicmanner. Themetabolismprocessis
slowandoccursmainlyviahydrolysisandN-acetylation[3].
Caspofungin’sfavorablesafetyprofileandrelativelylowpotentialfordrug–druginter-
actionsledtoitswidespreaduseintheprophylaxisandtreatmentofIFIs.However,reported
pharmacokinetic(PK)variabilitiesandsuboptimalexposurewithstandarddosing,espe-
ciallyincriticallyillpatients,increasetheriskofinsufficientefficacy[4,5]. Hence,person-
alizeddosagerecommendationsandtailoredadjustments,usuallyinformedbymeasured
observationsandmodel-predictedexposure,arecrucialtooptimizetreatmentoutcomes.
Caspofungindemonstratesaconcentration-dependentinhibitionoffungalgrowth[6].
The clinical efficacy of caspofungin in treating invasive aspergillosis relies on defined
pharmacokinetic/pharmacodynamic(PK/PD)indices,likepeakconcentration/minimum
effectiveconcentration(C /MEC),theareaunderconcentration–timecurve/minimum
max
inhibitoryconcentration(AUC/MIC),andAUC/MEC[7,8]. Commontargetsincludethe
ratioofthe24htotaldrugAUCtoMIC(AUC /MIC)andtheratioofthe24hfree
0–24h
drugAUCtoMIC(fAUC /MIC)[9,10]. AUC /MIC,themostinfluentialPK/PD
0–24h 0–24h
index for caspofungin, exhibits substantial variability among intensive care unit (ICU)
patients[11,12]. Despitepreclinicalsupport,thesetargetshaveyettobeconfirmedand
validatedinclinicalstudies,posingchallengesintheirapplicationtoclinicalpractice.
Populationpharmacokinetic(popPK)modelsdescribethePKprofilesofthestudied
populationandcanevaluatetheeffectofvariouscovariatesonPKvariabilities. Wheninte-
gratedwithBayesianforecasting,whichcombinespriorknowledgewithnewobservational
data,thisapproachhasbecomeincreasinglyutilizedfordesigningandadjustingdosing
regimensinclinicalpractice[13]. TheBayesianmethodrequiresawell-definedstructural
modelthatincludesparametersinformedbypriordistributionsandiscontinuallyupdated
withnewclinicalobservations,ensuringthatdosingregimensaretailoredtothespecific
needsandresponsesofpatients. DespitenumerousPK/PDstudiesoncaspofungin,ex-
istingmodelinformationhasnotbeenquantitativelyintegratedtoguidefurtherresearch.
Therefore,amodellibrarywouldbeinvaluableforfacilitatingmodel-informedprecision
dosing(MIPD)strategiesbycompilingrelevantdata.
This study aimed to develop a caspofungin population pharmacokinetic (popPK)
libraryanddemonstrateitsutilitybyassessingtheprobabilityoftargetattainmentacross
diversesettings. Thisconsistedofthreespecificobjectives: (1)toidentifyandre-implement
existingpopPKmodelsusinganopen-sourceRpackage;(2)toperformaqualitycontrol
of the developed model library by comparing PK metrics and evaluating the impact
of covariates; and (3) to demonstrate the utility of the model library by assessing the
probabilityoftargetattainment(PTA)acrossdiversestudysettings.
2. MaterialsandMethods
2.1. DevelopmentofModelLibrary
2.1.1. SearchStrategy
Fourdatabases,includingPubMed,Embase,WebofScience,andScopus,weresearched
forpopPKmodelstudiesofcaspofunginpublishedbefore25November2022,following
thePreferredReportingItemsforSystematicReviewsandMeta-Analyses(PRISMA)guide-
lines[14]. Thesearchstrategyencompassedkeywordspertinenttothefocalmedication
(‘Caspofungin’or‘Cancidas’or‘MK0991’or‘L743,872’),alongwithtermsspecificallydenot-
ingpopPKmodelingapproaches,suchaspopulationpharmacokinetic,NONMEM,MONO-
LIX,ornlmixr. Additionally,allreferencelistsfromselectedarticlesweresearchedtoensure
thecomprehensivenessofourstudy. Twoindependentauthorsconductedtheliterature
Pharmaceutics2024,16,819 3of23
research,andanothertwoseniorinvestigatorsperformedthedatavalidation[14]. Thecom-
prehensivesearchstrategiesemployedforeachdatabase,aswellasthedetailedinclusion
andexclusioncriteriautilizedinthestudy,canbefoundintheSupplementaryMaterials.
Allstudiesidentifiedfromthedatabasesandothersourceswerescreenedtoevaluate
theireligibilitybasedonthefollowingconsolidatedcriteria: (1)thesubjectofthestudies
was human, including healthy volunteers and patients; (2) caspofungin was the study
drug; (3)popPKorPK/PDanalysiswasconductedinthestudy; and(4)thestudywas
publishedinEnglish. Apublicationwasexcludedif(1)itwasnotanarticleoronlyfocused
onthemethodology, algorithms, orsoftwarecomparisonsor(2)criticalPKparameters
wereinsufficient.
2.1.2. LiteratureEvaluation
Literatureevaluationswereimplementedtodiligentlyidentifyandresolveanyanoma-
liesorinconsistenciespertinenttotheconstructionofthemodellibrary[15]. Thequality
ofthepopPKstudywasevaluatedbasedonachecklistwith33itemsadaptedfromthe
guidelines(seeSupplementaryMaterials)[16,17]. Theliteratureevaluationwasdivided
intofiveparts: titleandabstract,introduction,methods,results,anddiscussionandcon-
clusion. A risk of bias assessment was conducted. Each item received one point if the
study information met the criteria; otherwise, zero points were assigned. Compliance,
reflectingpopPKstudyquality,wascalculatedascompliance%=(itemsreported/total
items)×100%. Theriskofbiasplotwasconductedusingthe“ggplot2”package(version
3.3.5;https://ggplot2.tidyverse.org,accessedon5November2022)inRsoftware(version
4.1.1;http://www.r-project.org,accessedon5November2022).
2.1.3. DataExtraction
Astandardizeddataextractionmethodwassystematicallyemployedtofacilitatedata
collectionfromalleligiblestudies. Thisprocessencompassedthefollowingkeyaspects:
(1)demographiccharacteristics(e.g.,race,age,sex,andweightrange);(2)thestudydesign
(e.g.,typeofstudy,numberofsubjectsandobservations,dosageregimens,administration,
samplingschedule,anddetectionmethod)[16];(3)popPKmodelingcharacteristics(e.g.,
software/algorithm,finalPKparameters,modelvalidation);(4)investigatedandidenti-
fiedcovariatesinformationin popPKmodels; (5)PK/PDtargetsusedforsimulationif
applicable;and(6)modelapplicationandrecommendeddosageregimens.
2.1.4. ModelRe-Implementation
Afterextractingallrelevantinformationfromthemodels,were-implementedthem
usingtheopen-sourceRpackage“rxode2”package(version2.0.12;https://nlmixr2.github.
io/rxode2/index.html,accessedon8December2022),withallparameterssettothefinal
parameterestimatesreportedintheliterature. Allofthemodelcodesareprovidedinthe
SupplementaryMaterials.
2.2. QualityControlofModelLibrary
2.2.1. ComparisonofStudies
Qualitycontrol(QC)measureswereimplementedtoscreenandresolveanydiscrep-
anciesorissuesarisingduringtheestablishmentofthemodellibrary,ensuringrigorous
standards were maintained. We constructed three age-stratified virtual patient cohorts
(comprisinginfants,children,andadults),thoughtfullydesignedtoaccuratelymirrorthe
specifictargetpopulationoftheircorrespondingmodels.
Virtualpopulationswerecreatedanddividedintothreeagegroups: infants(10kg,
75cm,1yearold),children(20kg,100cm,6yearsold),andadults(70kg,40yearsold).
Infants and children adopted the standard dosage regimen, 70 mg/m2 on the first day,
followedby50mg/m2 oncedaily,whereasadultsfollowedadifferentdosageregimen:
70 mg on the first day, followed by 50 mg once daily. Caspofungin was administered
intravenouslyoveronehourtoallgroupsoncedaily. TheMostellerformula[18]wasused
Pharmaceutics2024,16,819 4of23
to calculate body surface area (BSA) values for infants and children, which were set at
0.441m2 and 0.79 m2, respectively. All patients reached a steady state with the labeled
dosingregimen. Concentration–timeprofilesweresimulatedwiththe“rxode2”package
(version2.0.12;https://nlmixr2.github.io/rxode2/index.html)inR.
Weconductedasimilaritycomparisonassessmenttoensuretheaccuracyofconstruct-
ingthedevelopedmodellibrary. Theideabehindthisassessmentisstraightforward. Ifthe
modelshavebeenaccuratelyimplemented,theconcentration–timecurvesforthemodels
withsimilartargetpopulationsshouldbecomparableastheydescribethePKbehaviorof
thesamedruginthesamepopulation. Themodelperformanceisconsideredcomparableif
itstypicalmaximumconcentration(C )fallswithintherangeof50–200%ofthemedian
max
C acrossallstudies(seeSupplementaryMaterials).
max
2.2.2. AssessmentofCovariatesImpact
Clearance(CL)isacrucialparameterforAUC,whiletheapparentvolumeofdistribu-
tion(V )isanimportantPKparameterforC . AUCandC playcentralrolesinthe
d max max
individualizeddosingofcaspofungin. Thus,comparingtheeffectsofdifferentcovariates
on CL and V was necessary. The effect of covariates was presented through a forest
d
plotusingthe“ggplot2”package(version2.0.0;Tidyversepackages)inR.Forcontinuous
covariates,themaximumandminimumvaluesfromtheincludedstudieswereextracted
andusedforcalculatingtherangeoftheeffectofdifferentcovariatesonCLorV . For
d
covariatesincludedinmultiplestudies,auniformrangewassetupforthecomparison
basedonthedemographicinformationintheincludedstudies. Forbinarycovariates,such
asdiseasesituation. Theuncommoncondition(criticallyilldisease)wastreatedasthe
reference(COV =0),whiletheuncommoncondition(notcriticallyilldisease)wastreated
i
asthetest(COV =1). CL =CL +CL ×COV. TherangeofCL was[CL ,
i i common diff i i common
CL +CL ](ifCL >0)or[CL +CL ,CL ](ifCL <0). Then,the
common diff diff common diff common diff
valuesofCLandVdwerefurthernormalizedbythereferencetothemediancovariate
value(equation). Weregardedcovariateeffectsbeyondthe80–125%rangeasclinically
significant,inaccordancewiththestandardemployedinbioequivalencestudies[19].
Upperorlowerlimit
Theeffectvalueof covariates = ∗100%
Referencevalue
2.3. ApplicationofPopPKModelLibrary
Louieetal. reportedcomparableCandidaalbicansreductionsinkidneytissueand
proposed AUC /MIC as the optimal PK/PD index for caspofungin [20]. Based on
0–24h
the invivo PK/PD studies, the PK/PD targets for C. albicans, C. glabrata, and C. parap-
silosis were 865, 450, and 1185, respectively [10,21]. According to the clinical and labo-
ratorystandardsinstitute(CLSI)MICbreakpointfortheinvitrobrothdilutionsuscepti-
bility testing of Candida spp., MICs for each Candida species were selected (C. albicans,
susceptible≤0.25mg/L;C.glabrata,susceptible≤0.12mg/L;C.parapsilosis,susceptible
≤2mg/L)[22]. AfterthepopPKmodellibraryofcaspofunginwasestablished,aMonto
Carlo simulation was conducted to predict the probability of caspofungin reaching the
PK/PDtargetunderlabeleddosingregimensandspecificMIC.Thestepswereasfollows:
(1)simulatePKprofilesofcaspofungin;(2)calculatethesteady-stateAUC usingthe
0–24h
trapezoidalmethod;and(3)calculatethePTAunderspecificMICsettings.
3. Results
3.1. OverviewofIncludedPopPKStudiesforCaspofungin
3.1.1. IdentificationofIncludedStudies
Figure1presentsthePRISMAflowchartforstudyidentification. FromPubMed,Sco-
pus,WebofScience,andEmbase,26,150,185,and61studieswereretrieved,respectively,
withnoadditionalrecordsfromothersources. Atotalof13studieswereincludedinour
modellibraryforsubsequentanalysis.
Pharmaceutics2024,16,819 5of23
Figure1.PRISMAflowdiagramfortheidentificationofcaspofunginpopulationpharmacokinetics
(PPK)studies.
3.1.2. EvaluationofLiterature
TheriskmapconcerningthebiasoftheliteratureissummarizedinFigure2. Two
studies lacked a description of PK data in their background sections, and two did not
includethesamplingschedule. Onestudydidnotmentionthedrugformulation,bioana-
lyticalmethods,andthedistributionofindividualmodelparameters. Noneoftheincluded
studies detailed the methods of handling missing data, and fewer than 20% of studies
reportedaspecificwayofhandlingthedatabelowthequantificationlimit. Nevertheless,
allstudiesachievedacompliancerateof85%,indicatingthatallstudiesareofgoodquality.
3.1.3. StudyandPopPKModelCharacteristics
ThecharacteristicsofeachstudyaresummarizedinTable1. Allincludedstudieswere
publishedfrom2011to2022,withnine[23–31]beingclinicaltrialsandfour[11,12,32,33]
beingobservationalstudies. Thetotalnumberofparticipantsrangedfrom12to299(IQR
(19,48)). Wangetal.[30]andWuetal.[29]enrolledbothpatientsandhealthysubjects,
while the others only enrolled invasive candidiasis patients. Three studies enrolled a
pediatricpopulationbetweenthreemonthsand18years,whiletherestincludedadults
only. Fivestudiesfocusedontransplantpatients,includingallogeneichematopoieticstem
celltransplant[25,32],hearttransplant[29],lungtransplant[30],andlivertransplant[26].
While most studies collected only plasma concentrations, Pressiat et al. [26] collected
plasma and peritoneal fluid samples. Sparse sampling strategies were adopted in all
three pediatric and two adult studies [23,34], with various bioassay methods used to
determinecaspofunginconcentrations. Despitemethodologicaldifferences,steady-state
plasmaconcentrationsunderstandarddosingregimensremainedabovethelowestlimits
ofquantitation(LLOQ,range[0.084–0.6mg/L]),suggestingtheirminimalinfluenceon
theresults.
Pharmaceutics2024,16,819 6of23
Figure2.Evaluationoftheincludedpopulationpharmacokineticsstudies(theriskbiasplot).
The modeling strategies and final PK parameters of the included studies are sum-
marized in Table 2. Ten studies [11,12,23,27–30,32–34] used NONMEM software, with
first-order conditional estimation with interaction (FOCE-i) being the most used algo-
rithm[11,12,23,27,28,32–34]. Moststudiesemployedatwo-compartmentmodeltodescribe
caspofungin PKs, although two studies [25,34] utilized a one-compartment model due
to sparse sampling schedules that may not accurately represent the characteristics of a
two-compartmentPKmodel.
Allstudiesincorporatedbetween-subjectvariability(BSV),withamedianof27.5%
(range: 11.8–42.3%) in CL across the 13 studies. Residual unexplained variability was
describedbyproportional[11,23,25–28,31–34],additive[12,30],orcombinedmodels[29].
Proportional errors with coefficients of variation ranged from 12.2% to 36% in eleven
studies,whilethreestudies[12,29,30]includedaddictiveerrorsrangingfrom0.0941to0.73
mg/L.Anintegrationofinter-occasionvariabilityonCLwasestimatedtobe17.2%and
ff
16.0%instudiesbyGastineetal.[33]andWürthweinetal.[28],respectively.
AllincludedpopPKmodelsconductedinternalvalidation, includinggoodness-of-
fit tests, a visual predictive check, a predicted–corrected visual predictive check, and
normalized prediction distribution error plots. Additionally, ten [11,12,25,27–30,32–34]
outofthirteenstudiespresentedresultsofbootstrapanalyses. Würthweinetal.[28]used
externalvalidationtofurtherverifytheirmodel.
Tenstudies[11,12,23,25–27,29,31,33,34]performedMonteCarlosimulationstoevaluate
existing dosing regimens or optimize caspofungin therapy, comparing different dosage
regimensorevaluatingcaspofunginPKsanddruginteractioninspecificpatientpopulations.
Innine[11,12,23,25,26,29,31,33,34]ofthesestudies,thesimulationtargetedAUC /MIC
0–24h
asthePK/PD.Pressiatetal.[26]concludedthatthestandardcaspofungindosewassuffi-
cient,whilefivestudies[11,12,23,29,34]explicitlyadvocatedforadjustingdosingregimens
basedoncovariates,suggestinghigherdoses(70–150mg)consideringfactorslikedisease
condition,albumin(ALB)levels[29],fungalcolonytype,andliverfunction.
Pharmaceutics2024,16,819 7of23
Table1.Characteristicsofincludedpopulationpharmacokineticsstudies.
Age(Years) Weight(kg) DailyDose
Study Country Numberof
BasicEntry Numberof Mean±SD Mean±SD Mean±SD Bioassay
(Publication (Typeof Subjects SamplingSchedule
Standard Observations Median Median Median [LOQ]
Year) Study) (Male/Female)
[Range] [Range] [Range]
Day1andDay4:
immediatelybefore
administration;
70mgQDon
Adultsallo-HSCT 0.5to1.5h,1.5to3h,3to5h,
Würthwein day1,followed
Germany 19 recipients, 5to11h, 43.4 71.2 HPLC
etal. 239 by50mgQD,
(clinicaltrial) (11/8) immunocom- and22to23hafter [20.1–57.6] [56–99.2] [0.15mg/L]
(2011)[32] IVinfusion
promized administration;
over60min
Thereafter:randomtime
pointstwiceweeklyuntilthe
endoftreatment
day1(immediatelypriorto
70mg,QD;
Adultswith dosingand2h[peaklevel],
100mg,QD;
Würthwein invasive 3h,5to7h,and24h[trough LC-MS/MS
Germany 46 61 76 150mg,QD;
etal. Aspergillosis, 468 level] [0.084
(clinicaltrial) (21/25) [18–74] [43–104] 200mg,QD,
(2013)[28] immunocompro- afterthestartofinfusion); mg/L]
IVinfusion
mized peakandtroughtimepoints
over120min
ondays4,7,14,28h
Pérez-Pitarch Day3andlater:predose,0.5,
Spain 12 Criticallyilladults 73 75 HPLC
etal. 105 1,1.5,2,2.5,3,5,7,9,24h NR
(clinicaltrial) (6/6) onCVVHD [56–78] [60–88] [NR]
(2018)[12] afterthestartofinfusion
70mg/m2
6.07±2.74 22.78±8.71
Yangetal. France 48 (loadingdose HPLC/MS
ChildreninICU 159 NR 5.09 21
(2019)[27] (clinicaltrial) (28/20) onday1), [0.25mg/L]
[2.05–11.77] [11.8–47.5]
50mg/m2QD.
ECMOgroup AdultsonECMO 65 64
12(9/3) afterLT [60–67] [59–69.3] UPLC-
Wangetal. China predose,0.5,1,2,4,8,12,24h
Adultpatients 271 50mgQD MS/MS
(2020)[30] (clinicaltrial) Controlgroup afterthestartoftheinfusion 59 65
neveronECMO [0.39mg/L]
7(5/2) [56–62] [53–65]
afterLT
Pharmaceutics2024,16,819 8of23
Table1.Cont.
Age(Years) Weight(kg) DailyDose
Study Country Numberof
BasicEntry Numberof Mean±SD Mean±SD Mean±SD Bioassay
(Publication (Typeof Subjects SamplingSchedule
Standard Observations Median Median Median [LOQ]
Year) Study) (Male/Female)
[Range] [Range] [Range]
AdultPatientsin 50mgQDwith
France ICUwithproven a140mg
Baillyetal. 13 53 76.5 LC-MS/MS
(observational orsuspected NR 0,2,3,5,7,24hpostinfusion loadingdose,
(2020)[31] (10/3) [34–55] [60–85] [0.5mg/L]
study) invasive IVinfusion
candidiasis over60min
loadingdoseof
Niuetal. China 48 Childrenwith anopportunisticsampling 6.58±3.7 21.7±10.3 70mg/m2 HPLC
139
(2020)[25] (clinicaltrial) (31/17) allo-HSCT strategy [0.61–14] [7.5–54] followedby [0.6mg/L]
50mg/m2
70mg
intravenously
Borsuk-De Poland
30 53 74 onthefirstday HPLC
Mooretal. (observational ICUpatients 180 0.5,2,4,8,12,24h
(16/14) [28–76] [40–150] andat50mgi.v [0.18µg/mL]
(2021)[11] study)
onthe
consecutivedays
a70mg
China loadingdose
Lietal. 42 ICUpatientswith 56.82±16.39 59.18±11.40 LC-MS/MS
(observational 140 1,3,6,24honDay4 anda50mg
(2021)[23] (31/11) IFIs [20–88] [41–84.5] [0.2µg/mL]
study) maintenance
dose
CASI:1mg/kg
CASII:
50mg/m2
Gastineetal. Germany 48 Childrenaged 6 21.5
NR Day1,Day4andDay9 CASIII: NR
(2022)[33] (clinicaltrial) (26/22) 3–17 [0–16] [9.4–79.5]
70mg/m2
CASIV:
50mg/m2
Pharmaceutics2024,16,819 9of23
Table1.Cont.
Age(Years) Weight(kg) DailyDose
Study Country Numberof
BasicEntry Numberof Mean±SD Mean±SD Mean±SD Bioassay
(Publication (Typeof Subjects SamplingSchedule
Standard Observations Median Median Median [LOQ]
Year) Study) (Male/Female)
[Range] [Range] [Range]
HTxgroup HTxgroup HTxgroup
27 27HTx 50 59.5 1hIVinfusion
(22/5) [20–73] [43.5–76] atadoseof
Wuetal. China LC-MS/MS
non-HTx 414 predose,1,2,6,10,16,24h 50mgQD
(2022)[29] (clinicaltrial) Controlgroup Controlgroup [0.4mg/L]
group afteraloading
31non-HTx 58 62
31 doseof70mg
[22–78] [48–100]
(21/10)
Aloadingdose
of70mgand
then50mg
AdultLT 395plasma perday
Pressiatetal. France 20 recipients and predose,1,2,4,8,12,24h 45 72 (or70mgper HPLC
(2022)[26] (clinicaltrial) (9/11) admittedtothe 50PF D1,D3,D8 [40.7–50] [62–81] dayifthe [0.5mg/L]
liverICU samples recipient
>80kg),
IVinfusion
over1h
1.standard
dosage
regimenof
C samplesatinterval 70/50mg;
Patientswhohave min
windowsof22–24h 2.Patientswith
China beendiagnosed
Yangetal. 299 921plasma post-dose, 44 62.3 hepatic LC-MS
(observational withconfirmedor
(2022)[34] (207/92) samples othersamplesatinterval [18–99] [30–100] insufficiency [NR]
study) probable
windowsof0–12h received
candidiasis
and12–24hpost-dose 70/35mg;
3.patients
>75kgreceived
70/70mg
allo-HSCT:allogeneichematopoieticstemcelltransplantation;ECMO:Extracorporealmembraneoxygenation;HTx:Hearttransplantation;IFIs:invasivefungalinfections;LT:Liver
transplantation;PF:peritonealfluid;NR:notreported.
Pharmaceutics2024,16,819 10of23
Table2.Modelingstrategiesandfinalpharmacokineticsparametersofincludedstudies.
Study Between-
Software/ ResidualUnexplained Internal External Simulation Modeling
(Publication FixedEffectParameters(RSE) Subject
Algorithm Variability Validation Validation Target Application
Year) Variability(%)
CL(L/h) =0.462 25
Würthwein NONMEM/ V 1(L) =8.33 29 VPC NR Evaluatecovariate
etal. prop.err=21% GOF NR
FOCE-I Q(L/h) =1.25 / effects
(2011)[32] Bootstrap
V (L) =3.59 /
2
=0.411×[1+0.0102×
CL(L/h) 28.5
(BW-76)]
=5.85×[1+0.0102×
V (L) 28.8
1 (BW-76)] pcVPC
Würthwein
NONMEM/ VPC Evaluatecovariate
etal. Q(L/h) =0.843 / prop.err=14.3% 36/456 NR
FOCE-I GOF effects
(2013)[28]
V (L) =6.53 66.8 Bootstrap
2
IOV(CL) =0.16 /
Cor-CL-V =0.802 /
1
Ke(h−1) =0.0899 11.8 AUC/MIC:
C.albicans865;
Pérez-Pitarch V (L) =6.46×(BW/75)× 21.4 GOF C.glabrata450; Evaluatethe
etal.
NONMEM/ 1 [1–0.233×(TP-5.6)]
add.error=0.0941mg/L Bootstrap NR C.parapsilosis1185; efficacyof
FOCE-I
(2018)[12] K 12(h−1) =0.494 / VPC Cmax/MEC: differentdosages
Aspergillusspp.
K (h−1) =0.392 /
21 10–20
CL(L/h) =0.165×(BSA/0.79)1.3 24.2
Evaluatethe
GOF
Yang NONMEM/ V 1(L) =1.730×(BSA/0.79)1.5 / VPC efficacyofthe
etal. FOCE-I Q(L/h) =0.351 161.6 prop.err=19.6% NPDEs NR C min dosingregimen;
(2019)[27] describePKina
Bootstrap
V (L) =0.943 76.6 specificpopulation
2
Pharmaceutics2024,16,819 11of23
Table2.Cont.
Study Between-
Software/ ResidualUnexplained Internal External Simulation Modeling
(Publication FixedEffectParameters(RSE) Subject
Algorithm Variability Validation Validation Target Application
Year) Variability(%)
CL(L/h) =0.21×(OPT/5)1.3 20
Evaluatecovariate
Wang V (L)
=(2.21+SEX×0.62)×
10 GOF effects;
etal.
NONMEM/ 1 (OPT/5)0.93
Add.error=0.73mg/L VPC NR NR describePKina
NR
(2020)[30] V (L) =2.87 48.0 Bootstrap specific
2
population
Q(L/h) =0.84×(SOFA/7)1.98 /
CL(L/h) =0.98 42.3
AUC/MIC:
Bailly V (L) =9.01 42.6
Monolix/ 1 GOF 50,450,865; Evaluatedifferent
etal. prop.err=12.2% NR
(2020)[31]
SEAM Q(L/h) =5.12 79.9 VPC Cmax/MIC dosages
5,10,15,20
V (L) =11.9 77.2
2
=0.1×(BSA/0.79)0.89× GOF Dosing
eN ti au
l.
P Nh Lo Ie Mni Ex CL(L/h) (lnAST/3.38)−0.23 33.3
prop.err=26.6%
NV PP DC
Es NR AUC 24/MIC
ago ap inti sm ti Cz aa nti do in
da
(2020)[25] V 1(L) =1.36×(BSA/0.79) 32.9 Bootstrap spp.
CL
=0.563×(BW/70)0.75 24.7
(L/h)D1
CL
=0.737*(BW/70)0.75 24.7
(L/h)D2
AUC /MIC Evaluatecovariate
Borsuk-De CL 24
=1.01×(BW/70)0.75 24.7 pcVPC C.albicans865; effects;
Moor NONMEM/ (L/h)D3
prop.err=19.9% GOF NR C.glabrata450; describePKina
etal. FOCE-I
(2021) [11]
V 1(L)D1 =6.04×(BW/70) 28.6 Bootstrap C.parapsilosis specific
V (L)D2 =7.32×(BW/70) 28.6 1185 population
1
V (L)D3 =7.70×(BW/70) 28.6
1
Q(L/h) =1.31 /
V (L) =5.13 49.4
2
Cor-CL-V1 =0.868 /
Pharmaceutics2024,16,819 12of23
Table2.Cont.
Study Between-
Software/ ResidualUnexplained Internal External Simulation Modeling
(Publication FixedEffectParameters(RSE) Subject
Algorithm Variability Validation Validation Target Application
Year) Variability(%)
=0.323×0.89×
(35/ALB)1.27
(TBIL≤22µmol/L)
CL(L/h) 22.4
=0.323×(35/ALB)1.27 AUC 24/MIC
Lietal. NONMEM/
×(TBIL/22)0.265 pcVPC C.albicans865;
Evaluatecovariate
(2021)[23] FOCE-I
(TBIL>22µmol/L) prop.err=24% GOF NR C.glabrata450;
effects
NPDEs C.parapsilosis
V 1(L) =6.77×(WT/70)1.08 /
1185
Q(L/h) =0.923 /
V (L) =4.58 /
2
CL
(L/h/70 =0.790 27.5
kg) AUC /MIC:
24
C.albicans865;
Gastine
V 1(L/70
=7.75 31.5 GOF C.glabrata450;
Assessextended
NONMEM/ kg) twice-weekly
etal. prop.err=19.4% VPC NR C.parapsilosis
FOCE-I dosageusing
(2022)[33] Q(L/h/70 Bootstrap 1185;
=1.20 / caspofungin
kg) fAUC /MIC:
24
(10–20)
V (L/70
2 =5.29 15.1
kg)
IOV(CL) =17.2% /
=0.385×
CL(L/h) (ALB/37.42)−1.01 33.5
GOF
AUC 24/MIC:
Wu C.albicans865;
NONMEM/ V (L) =4.27 67.5 prop.err=13.4% Bootstrap Evaluatecovariate
etal. 1 NR C.glabrata450;
NR add.error=0.213mg/L VPC effects
(2022)[29] Q(L/h) =2.85 0.0 C.parapsilosis
NPDE
1185
V (L) =6.01 47.7
2
Pharmaceutics2024,16,819 13of23
Table2.Cont.
Study Between-
Software/ ResidualUnexplained Internal External Simulation Modeling
(Publication FixedEffectParameters(RSE) Subject
Algorithm Variability Validation Validation Target Application
Year) Variability(%)
CL(L/h) =0.38 33.0
V (L) =6.24 59.0
1 fAUC /MIC: Analyzethe
24
Pressiat Q(L/h) =2.58 / C.albicans25.9; PK/PDof
Monolix/ GOF
etal. prop.err=36% NR C.glabrata13.5; caspofungin
(2022)[26]
FOCE-I V 2(L) =6.44 107.0 pcVPC
C.parapsilosis inaspecific
K eff,13 =0.08 54 35.5 population
K =0.26 /
eff,31
=0.32×(1+0.46×
ALB*)×(1+0.98×
WT*)
(ALB*=1,ALB<35
CL(L/h) g/L; 29.2
ALB*=0,ALB≥35
g/L;
Evaluatecovariate
Yang
WT*=1,WT≥70kg,
Bootstrap
fAUC 24/MIC
effects;describe
NONMEM/ WT*=0,WT<70kg) C.albicans20;
etal. prop.err=19.3% GOF NR PK
(2022)[34] FOCE-I =13.31×(1+0.49× pcVPC C.glabrata7; inaspecific
C.parapsilosis7
ALB*)×(1+0.24× population
WT*)
(ALB*=1,ALB<35
V (L) g/L; 59.2
1
ALB*=0,ALB≥35
g/L;
WT*=1,WT≥70kg,
WT*=0,WT<70kg)
CL:clearance;Q:intercompartmentalclearance;V1:centralvolumeofdistribution;V2:peripheralvolumeofdistribution.
Pharmaceutics2024,16,819 14of23
Niu et al. [25] concluded that the current recommended dose of caspofungin was
sufficientforpediatricpatientsanddidnotrequirehigherdoses.Gastineetal.[33]reported
thatatwice-weeklyextendeddosingregimenof200mg/m2,withamaximaltotaldoseof
200mg,shouldyieldcomparableaverageweeklyexposurestotheapproveddaily-dosing
regimen. Additionally,Yangetal.[27]includedBSAasasignificantcovariateonbothCL
andV ,supportingtheadoptionofaBSA-baseddosingregimen.
d
3.2. OverviewofPopPKModelLibrary
3.2.1. ComparisonofCaspofunginPKProfiles
Simulated caspofungin concentration–time profiles are displayed in Figure S1. A
comprehensivecomparisonofallsimulatedPKparametersforcaspofunginisshownin
Figure3. ThemedianC valuesofchildren(23.56mg/L)andinfants(25.65mg/L)were
max
higherthanthatofadults(8.75mg/L),likelyduetothelowerV inchildrenandinfants
d
(adultsvs. pediatricpopulation: [2.21–9.01L]vs. [1.36–2.21L]).Moreover,thepediatric
populationdemonstratedahigherCLperkilogramthanadults,withweight-normalized
medianCLvaluesof0.0083L/h/kg(range:0.005–0.011L/h/kg)and0.0086L/h/kg(range:
0.006–0.011L/h/kg)forchildrenandinfants,respectively,comparedto0.0061L/h/kg
(range: 0.003–0.014L/h/kg)inadults.
Figure3.Caspofunginmainpharmacokineticparameter(AUC)atsteadystateof(a)infants,(b)chil-
dren,and(c)adults.Virtuallyallpatientswereassumedtobemaleandreceivedcaspofunginata
doseof70mgonthefirstday,followedby50mgonceadayasaninfusionfor1hforadultsand
70mg/m2onthefirstday,followedby50mg/m2onceadayasaninfusionfor1hforinfantsand
children[11,12,25–34].
Inthepediatricpopulation,threestudies[25,27,33]displayedsimilarPKcharacteristics
inbothinfantsandchildren. Amoffngadultpatients,Wangetal.[30]reportedhigherAUC
and C than other studies under the same dosage regimen, while Bailly et al. [31]
max
showedmuchlowerexposure. However,theremainingeightstudiesshowedsimilarPK
profilesdespitevariationsinpatients’diseaseconditions(FigureS1). ThesubjectsinWang
etal.’sstudy[30]werelungtransplantationrecipientsreceivingICUfollow-uptreatment,
exhibitinglowerCLandV .
d
3.2.2. CovariateScreeningandInfluenceAnalysis
AlltestedcovariatesthataffectedCL,V ,intercompartmentclearance(Q),andthe
d
distributionvolumeoftheperipheralcompartment(V )aresummarizedinTable3. The
p
stepwise covariate screening included forward inclusion and backward elimination. A
comparisonofidentifiedandinvestigatedcovariatesispresentedinFigure4.
Pharmaceutics2024,16,819 15of23
Table3.Investigatedandidentifiedcovariatesinpopulationpharmacokineticmodelsofincludedstudies.
TestedCovariates CovariateSelectionCriteria SignificantCovariates
Study
Co- Forward Backward
(PublicationYear) Demographic LaboratoryTests CL V1 Q V2
Administration Inclusion Elimination
Würthweinetal. Liposomal
Sex,Age,Weight,BSA TBIL,CLCR p<0.001 p<0.001 NR NR NR NR
(2011)[32] amphotericinB
Würthweinetal.
Dose,Sex,Age,Weight TBIL,CLCR NR p<0.05 p<0.01 Weight Weight NR NR
(2013)[28]
Pérez-Pitarchetal.
Age,Sex,Weight TP,SCR,TBIL,CLCR NR p<0.05 p<0.01 NR Weight,TP NR NR
(2018)[12]
Yangetal.
Age,Weight,BSA SCR,ALB NR NR p<0.05 BSA BSA NR NR
(2019)[27]
Wangetal. Age,Sex,Weight,BMI,ECMO, SOFA,ALT,AST,ALB,TBIL,
NR p<0.05 p<0.01 OPT Sex SOFA NR
(2020)[30] OPT,24hfluidbalance CLCR,PCT
Baillyetal. ALB,PAL,TBIL,AST,ALT,
Age,Weight,ECMO NR NR NR NR NR NR NR
(2020)[31] SCR,SOFA
Niuetal. CR,eGFR,ALB,TBIL,DBIL,
BSA,Weight, NR p<0.05 p<0.01 BSA,AST BSA NR NR
(2020)[25] ALT,AST,γ-GT
Borsuk-DeMooretal. Age,Weight,Height,Sex, SOFA,PCT,UF,ELWI,Cardiac
NR NR p<0.01 NR NR NR NR
(2021)[11] ECMO,CRRT,Survival,dose Output,ALB,TP,LiverFailure
Lietal.
Sex,Age,Weight ALT,AST,TBIL,ALB,CLCR NR p<0.05 p<0.01 ALB,TBIL Weight NR NR
(2021)[23]
Acyclovir,
Gastineetal.
Weight,Age,BSA,Sex,Race ALB,CLCR Vancomycin, p<0.05 p<0.01 Weight Weight Weight Weight
(2022)[33]
Dexamethasone
Wu.etal. Age,Sex,Weight,Height,BMI, ALB,CLCR,AST,ALT,DBIL,
NR p<0.05 p<0.001 ALB NR NR NR
(2022)[29] ECMO,CRRT TBIL,PCT,PLT,SCR,TP
Pressiatetal. ALB,TP,TBIL,SCR,CLCR,
Age,Sex,Weight,BMI NR p<0.05 NR NR NR NR NR
(2022)[26] SOFA,WBC,CRP,MELD,PT
Yangetal. Weight, Weight,
Weight,CMT,SOP,SOT,ICU ALB,MM,CYC,MET NR p<0.05 p<0.001 NR NR
(2022)[34] ALB ALB
BMI:bodymassindex;BSA:bodysurfacearea(calculatedaccordingtotheformulaofMosteller);ALB:albumin;eGFR:theestimatedglomerularfiltrationrate;CLCR:creatinine
clearance(determinedaccordingtotheformulaofCockcroftandGault);SCR:serumcreatinine;PCT:procalcitonin;TP:totalprotein;TBIL:totalbilirubin;DBIL:directbilirubin;Hb:
hemoglobin;AST:aspartateaminotransferase;ALT:alanineaminotransferase;PAL:phenylalanineammonia-lyase;ECMO:extracorporealmembraneoxygenation;CRRT:continuous
renalreplacementtherapy;SOFA:sequentialorganfailureassessment;OPT:operativetime;ELWI,extravascularlungwaterindex;UF:ultrafiltrationrate;PLT:platelet;WBC:leukocyte
count;CRP:C-reactiveprotein;MELD:modelforend-stageliverdisease;PT:prothrombintime;HT:hearttransplantation;NR:notreported.
ff
Pharmaceutics2024,16,819 16of23
Figure4.Ahistogramoftheamountofinvestigatedandidentifiedcovariatesinincludedstudies.
Fourstudies[11,26,31,32]didnotincludeanycovariates,likelycontributingtothe
highconsistencyoftheincludedpatients. Themostinfluentialcovariatewasbodysize,
suchasbodyweightandBSA.Three[15,19,34]studies(23.1%)foundbodyweightclosely
relatedtoCL,andfivestudies[12,23,28,33,34](38.5%)indicateditsimpactonV . Yang
d
et al. [27] and Niu et al. [25] identified BSA as a crucial covariate that affects both CL
andV . Moreover,threestudies[23,29,34]confirmedALBlevelasasignificantcovariate
d
affectingCL.Intheirfinalmodel,Niuetal.[26]andLietal.[24]includedtheliverfunction
biomarkerasacovariate. Interestingly,amongthestudiesincludingpediatricpopulations,
two [25,27] identified BSA as a significant covariate on CL and V , supporting dosing
d
basedonBSA.Würthweinetal.[28]foundthatthePKofcaspofunginwasnotalteredby
thecoadministrationofliposomalamphotericinB.Threestudies[11,29,30]investigating
thedifferenceinPKcharacteristicsinpatientgroupswhohadreceivedcontinuousrenal
replacementtherapy(CRRT)orextracorporealmembraneoxygenation(ECMO)concluded
thatthesefactorshadnosignificanteffect.
IdentifiedcovariatesonCLandV werevisualizedusingtheforestmapinFigure5.
d
Figure5AhighlightsBSAasapivotaldeterminantofCLinchildren,withweightsignifi-
cantlyinfluencingCLinadultandpediatricpopulations. Theimpactofbodysizemeasures
exceeds the conventional range (80–125%), suggesting considerable CL variability. De-
spite variations in covariates across studies due to different populations, the profound
influenceofbodysizeoncaspofunginCLremainsconsistent. Comparedtothereference
value, six[12,23,25,27,29,33]outofthesevenstudiesdemonstratedasignificantimpact
ofbodysizeonV withchangesgreaterthan20%underthenormalrangeofbodysize.
d
Additionally, two studies [12,27] showed the influence of ALB to exceed a 20% change
inV withinthenormalrange. Wangetal. foundthatmalegenderwasassociatedwith
d
increasedcaspofunginV (Figure5B).Lietal.[23]andNiuetal.[25]showedliverfunction
d
tohavechangesover20%underawiderangeofliverfunctions. Threestudies[23,29,34]
includedALBasasignificantcovariateaffectingCL,withchangesexceeding20%within
thenormalrangeoftheALBlevel.
ff
ff
Pharmaceutics2024,16,819 17of23
Figure5.(A)TheeffectofcovariatesonCL(L/h)ofcaspofungininincludedstudies.(B)Theeffectof
ff ff
covariatesonV (L)ofcaspofungininincludedstudies.Thehorizontalbarsrepresentthecovariate
d
effectonclearanceineachstudy.Thetypicalvalueofclearanceineachstudywasconsideredtobe1.
ff
Theeffectofeachcovariateforclearanceisdisplayedbytheratioofclearanceintherangeofeach
ff
covariatetothetypicalclearancevalue.Theshadedarearangesfrom0.8to1.25[23,25–30,33,34].
3.3. ModelLibraryApplications
Inourmodellibrary, 77%ofstudiesincorporatedAUC/MICasthePK/PDtarget
forsimulation. ThesimulatedPTAforeachpublishedpopPKmodelwasassessedwith
three Candida strains, the results of which are presented in Figure 6. For C. albicans
(MIC=0.25mg/L)andC.parapsilosis(MIC=2mg/L),noneofthepopulationsachieved
aPTAof≥90%. However,forC.glabrata(MIC=0.12mg/L),70%ofstudiesfocusedon
adultsreachedaPTAof≥90%,whileallpediatricpatientsachievedaPTAof≥90%. The
PTAresultssuggestedthatcaspofunginmaybeunderexposedinadultpatients,indicating
≥
thenecessityofbasingdrugdosageontheCandidastrains’resultsandthecorresponding
MICvalue.
≥ ≥
Pharmaceutics2024,16,819 18of23
Figure6.Theprobabilitytargetachievementofcaspofungininincludedstudies.Thereddashedline
representsa90%targetattainmttentrate,whilethethreeverticallyorienteddashedlinesofdifferent
colorscorrespondtotherespectiveclinicalbreakpointsforMICsofeachfungus[11,12,25–34].
4. Discussion
Numerous PK studies on caspofungin have been conducted recently, with several
popPKstudiesaimingtoexplainPKvariability. Toourknowledge,thisstudywasthefirst
tobuildandshareaparametricpopPKmodellibraryofcaspofungin. Thelibraryischar-
acterizedbysimulationsofconcentration–timeprofilesandcovariateeffectassessments,
wherewedemonstratedthepotentialoftheconstituentmodelsinestimffatingtheAUC,
C ,andPTAofcaspofungin. Thisworkprovidesevidenceforadvocatingindividualized
max
dosing not only based on body size but also potential covariates such as liver function
andhypoalbuminemia.
4.1. PediatricPatients
The PKs of caspofungin vary substantially among pediatric patients. All three pe-
diatricstudieswithinthemodellibraryconsistentlyappliedallometricscaling,aligning
withthestandardpediatricdosingapproachthatutilizesbodysurfaceareaasthebasis
for medication administration. Children showed higher CL (L/h/kg) than adults per
kilogram,possiblyduetodifferencesindistributionratesintohepatictissue. Invitrodata
suggestedtheinvolvementofuptaketransporters,suchasOATP1B1,incaspofungintissue
ff
distribution,particularlyinhepaticuptake[35]. Studies[24,36,37]suggestedthatfactors
likeacceleratedliveruptake,largerliver-to-bodyratios,andincreasedhepaticbloodflow
contributetoheightenedcaspofunginCLininfantsandtoddlers. However,conflicting
findingsexistregardingage-dependentdifferencesinhepaticOATP1B1expressionandits
impactoncaspofunginuptake. Thomsonetal. reportednoage-dependentdifferencesin
ff
hepaticOATP1B1expressionacrosspediatricgroups. Sáez-Llorensetal.[38]suggested
ff
that caspofungin CL increases from infancy to childhood and then decreases through
adolescenceintoadulthood. PediatricpatientsgenerallyexhibithigherCL(L/h)andV
d
(L) compared to adults under standard dosing regimens, attributed to factors such as
reducedbloodflow,higherbodyfat-to-leanmassratios,anddecreasedtotalbodywater.
Thesephysiologicalandpathologicaldistinctions,particularlypronouncedininfants,can
significantlyinfluencecaspofungin’sabsorption,distribution,metabolism,andexcretion.
Pharmaceutics2024,16,819 19of23
Findingsfromincludedstudiesindicatedthatadjustingthecaspofungindailydose
basedonBSA,ratherthanweight,mightbemorereasonableinpediatricpatients. Three
studies[25,27,33]focusedonchildrenwithamedianageofaroundsixyearsusedbodysize
forallometricscaling;oneincludedweight,andtwostudiesincludedBSA.Gastineetal.
(48subjects)estimatedweight-normalizedCLandV ,implicitlyassumingthepowerof1
d
fortheimpactofweightonCLandV . Niuetal. (48subjects,139observations)showed
d
that the power of BSA on CL was estimated to be 0.89 (RSE 11.36%), and the power of
BSAonV wasfixedto1,respectively. InYangetal. (48subjects,159observations),the
d
power of BSA on CL and V was estimated to be 1.3 (RSE 13.8%) and 1.5 (RSE 13.5%).
d
Overall, the body size metrics have positive correlations with CL and V . Due to the
d
under-power design of the study [39], the slight deviations in the estimated exponents
fromthetheoreticalallometricrelationshipshouldbeinterpretedwithcaution.
Sáez-Llorensetal.[38]foundthataBSA-baseddosageof25mg/m2QDinneonates
underthreemonthsachievedplasmaconcentrationprofilessimilartoadultsreceivinga
standard50mgdailydose[38]. However,PKvariabilitywashigherinpediatricpatients
withalowerbodyweight,necessitatingindividualizeddoseadjustments. BeyondBSA-
based dosing, considering blood biochemical parameters and physiological conditions,
suchasserumALBlevel,hepaticfunction,andbloodflow,iscrucial. Caspofunginisocca-
sionallyusedinverylow-birth-weightinfants,butPKdataforthisgrouparescarce[40].
Thisscarcityemphasizesthenecessityforlarge-scale,prospectivetrialstoestablishcaspo-
fungin’sefficacy,safety,optimaldosage,androleinneonatalcandidiasis,particularlyin
infantsunderthreemonthswithaverylowbirthweight.
4.2. AdultPatients
Insufficientdrugexposureiscommonwiththelabeleddosingregimeninadultpa-
tients. Inthismodellibrary,fiveofthetenadultstudiesproposedincreasingthedosage
ofcaspofungintoachievetargetexposurelevels. Caspofungindosingdifferencesexistbe-
tweenadultsandchildren. Loweradultdosagescorrespondtolowerdrugconcentrations
overtimecomparedtochildren(FigureS1),indicatinganeedfordosingstrategyimprove-
ment. Inpatientswithnormalliverandkidneyfunction,hypoalbuminemiacanresultin
elevated levels of unbound drugs, potentially leading to an increased CL, especially in
highlyprotein-boundantibioticslikecaspofungin. Additionally, asahydrophilicdrug,
caspofungin’sV mayincreaseduetofluidshiftsandextensivefluidresuscitation[41,42].
d
Criticallyillpatientsoftenpresentwithconcomitantconditionssuchasobesity,hepatic
impairment, and specific infusion regimens, contributing to the high BSV of caspofun-
gin PKs [43]. Treatment modalities like ECMO and CRRT are frequently employed in
ICUsettings. StudieshaveyieldedconflictingresultsregardingtheimpactofECMOon
caspofunginCL,withonestudy[30]suggestinganincreaseandanother[31]findingnodis-
cernibleeffect,likelyduetocaspofungin’shighsolubilityinwaterandmethanol. Critically
illpatientsexhibitlowercaspofunginexposurecomparedtohealthysubjects[5]. Bettsetal.
supportedawidesafetymarginforcaspofungin,allowingforhigher-dosetherapyupto
150mgdailyifclinicallyindicated[44]. However,argumentsagainstreducingcaspofungin
dosesincriticallyillpatientswithhypoalbuminemiaandabnormalliverfunctionsuggest
thatauniform,flatdosingstrategymaynotbeoptimal[45]. Consensusleanstowardsthe
importanceoftherapeuticdrugmonitoringincriticallyillpatientswithhypoalbuminemia,
withorwithoutabnormalliverfunction,orincaseswherestrainswithelevatedminimum
inhibitoryconcentrationsneedtobeaddressed.
Borsuk-DeMooretal.[11]notedatime-varyingCLofcaspofungininICUpatients:
0.563L/honday1,0.737L/honday2,and1.01L/honday3,respectively. Thisescalating
CLmaydecreaseAUCandimpairefficacy,butfewmodelsconsideredtime-dependentvari-
ables. Theextendedmonitoringofcaspofungintherapyisrecommendedforpersonalized
medicationoptimization.
Pharmaceutics2024,16,819 20of23
4.3. TowardsPrecisionDosing
The model library of caspofungin popPK models developed in this study has the
potential to accelerate the implementation of MIPD. Leveraging our model library, re-
searchers could rapidly perform external validations on their data, efficiently selecting
themostappropriatemodelforlocaluse,therebyspeedingupindividualizeddosing[46].
Integrationwiththe“PopED”packagefurtherenhancesitsutilitybyallowingtheselection
ofpublishedlibrarymodelsaspriorinformationforclinicaltrialdesign.
However, translating preclinical PK/PD targets into clinical benchmarks remains
challenging. Investigations into the MIC of caspofungin are notably limited, chiefly at-
tributabletothechallengesincultivatingfungus,theextendeddurationofexperimental
procedures,andaninadequatefavorablereturnoninvestment. Notably,arecurringtheme
acrossstudiesisthelackofwell-establishedclinicalPK/PDtargets,leadingtorelianceon
preclinicalcounterparts. CLSIguidelinesspecifyMICbreakpointsforCandidaspp. invitro
brothdilutiontests,butsignificantdifferencesinMICsamongbacterialspeciesunderscore
theimportanceofbacterialcultureinclinicalpractice. Inourmodellibraryaboutadults,
PK/PDcut-offvaluesvaryforC.albicans,C.glabrata,andC.parapsilosis. Thesefindings
suggestsignificantvariabilityinestablishingcaspofungincut-offvaluesacrosspopulations,
posingchallengesforcliniciansandresearchersindeterminingoptimaldosingstrategies.
Forcaspofungin,thecurrenttargetvaluesarederivedfrompreclinicalstudiesandarein
urgentneedofconfirmationthroughclinicalresearch.
DisparitiesinPKprofilesbetweenpediatricandadultpopulationshighlighttheneed
forfurtherresearch. ThepediatricandadultpopulationsexhibitmarkeddisparitiesinPK
profiles,particularlywithmuchhighercaspofunginexposurelevelsobservedinchildren
comparedtoadults,upto1.5timesgreaterwithstandarddosingregimens. Thisdiscrep-
ancymaystemfromtwopotentialreasons: differencesinthePK/PDrelationshipbetween
childrenandadultsandtheneedtooptimizethecurrentdosingregimen,suggestingeither
doseincreasesforadultsordecreasesforchildren. However,duetolimitedresearchin
pediatricpopulations,furtherPK/PDstudiesinthispopulationareessentialtoelucidate
theunderlyingcauses.
Additionally, assessing the concentration of the free drug is essential, as only the
unboundformexertstherapeuticeffects,thoughthisaspectisoftenoverlookedinstudiesof
caspofungin. Reducedplasmaproteinlevelsinvitrowerefoundtoincreasetheantifungal
activityofcaspofunginandlowerthepharmacodynamictargetAUC /MIC,likelyby
total
increasingthefreeconcentration[47]. However,noneoftheincludedstudiesmeasured
freecaspofunginconcentrations. IncaseswherefAUC /MICwasemployedasthe
0–24h
PK/PDtarget,itwascalculatedbasedonthetotalAUC/MICtargetandcaspofungin’s
plasmaproteinbindingrateof97%.
4.4. Limitations
Our research has certain limitations. Firstly, due to the limited number of studies
involvingpediatricpatients,wewereunabletocomprehensivelyinvestigateandcompare
thePKofchildrenandinfants. Furthermore,asthismodellibraryfocusedonsummarizing
significantcovariatesinfluencingcaspofunginPKsandcomparingpopPKmodelingacross
different age groups, we only replicated the published models to align with our study
objectives and the characteristics of the medications under investigation. Additionally,
PK/PD targets for PTA calculation were derived from invitro data provided by CLSI,
whichmayleadtodiscrepanciesinPTAaccuracyduetotheabsenceofinvivostudiesin
humans. Finally,ourstudywasrestrictedtotheEnglish-languageliterature,potentially
omittingrelevantstudiespublishedinotherlanguages.
5. Conclusions
Themodellibraryofparametricpopulationpharmacokineticmodelsforcaspofungin
ishelpfulinpromotingmodel-informedprecisedosing. Theoptimizationofthecaspo-
fungindosingregimenshouldconsiderthepatient’sliverfunctionandhypoproteinemia.
Pharmaceutics2024,16,819 21of23
Additionally,prospectivePK/PDstudiesofcaspofungininpediatricsarewarrantedto
elucidatetheexposure–responserelationshipassociatedwiththismedication.
SupplementaryMaterials: Thefollowingsupportinginformationcanbedownloadedat: https:
//www.mdpi.com/article/10.3390/pharmaceutics16060819/s1,FigureS1:Thesteady-stateconce-
ntration-timeprofilesofpiperacillinfor(a)infants,(b)children,and(c)adultswheninfusedinter-
mittently. Thesolidlinerepresentsmedianofthesimulatedconcentration-timeprofile. Thelight
shadowsrepresentthe10th–90thpercentilesofthesimulatedconcentration-timeprofiles.Allvirtual
patientswereassumedtobemalereceivedcaspofunginatadoseof70mgonthefirstday,followed
by 50 mg once a day as infusion for 1 h for adults and 70 mg/m2 on the first day, followed by
50mg/m2onceadayasinfusionfor1hforinfantsandchildren.FigureS2:CheckList.
AuthorContributions:Conceptualizationandmethodology,N.X.,Y.S.andX.Z.;datacuration,W.M.
andY.W.(YixueWang);softwareandvalidation,W.Y.,Q.H.andY.W.(YixueWang);formalanalysis,
N.X.andY.S.;investigation,W.M.andK.W.N.;visualization,N.X.,Y.W.(YueWu)andW.Y.;resources,
Z.T.,Y.W.(YueWu),X.X.,Q.H.andG.Y.;writing—originaldraftpreparation,N.X.andY.S.;writing—
reviewandediting,W.M.,K.W.N.,Y.W.(YueWu),Z.T.,G.Y.andX.X.;projectadministration,Z.T.
andX.X.;supervision,Q.H.,G.Y.,X.X.andX.Z.;fundingacquisition,X.Z.Allauthorshavereadand
agreedtothepublishedversionofthemanuscript.
Funding: Y.W.(YixueWang)receivedresearchfundingfromtheNationalKeyResearchandDe-
velopmentProgramofChina(2021YFC2701800,2021YFC2701805).X.Z.receivedresearchfunding
fromtheShanghaiMunicipalHealthCommissionClinicalResearchYouthProject(No.20224Y0121),
theHunanKeyLaboratoryforBioanalysisofComplexMatrixSamples(FZJZ-202305),theNational
NaturalScienceFoundationofChina(No.82204544),andtheFudanUniversityScientificResearch
FoundationforTalentedScholars(No.JIF301052).
InstitutionalReviewBoardStatement:Notapplicable.
InformedConsentStatement:Notapplicable.
DataAvailabilityStatement:Thedatageneratedduringand/oranalyzedduringthecurrentstudy
areavailablefromthepublishedliterature.
Acknowledgments: TheauthorswouldliketothankMengGufromFudanUniversityfortheir
criticalcommentsandsuggestionsregardingthedatavisualization.
ConflictsofInterest:Theauthorsdeclarenoconflictsofinterest.
References
1. Pappas,P.G.;Kauffman,C.A.;Andes,D.R.;Clancy,C.J.;Marr,K.A.;Ostrosky-Zeichner,L.;Reboli,A.C.;Schuster,M.G.;Vazquez,
J.A.;Walsh,T.J.;etal.ClinicalPracticeGuidelinefortheManagementofCandidiasis:2016UpdatebytheInfectiousDiseases
SocietyofAmerica.Clin.Infect.Dis.2016,62,e1–e50.[CrossRef][PubMed]
2. Hope,W.W.;Castagnola,E.;Groll,A.H.;Roilides,E.;Akova,M.;Arendrup,M.C.;Arikan-Akdagli,S.;Bassetti,M.;Bille,J.;Cornely,
O.A.;etal.ESCMID*guidelineforthediagnosisandmanagementofCandidadiseases2012:Preventionandmanagementof
invasiveinfectionsinneonatesandchildrencausedbyCandidaspp.Clin.Microbiol.Infect.2012,18(Suppl.S7),38–52.[CrossRef]
[PubMed]
3. HIGHLIGHTSOFPRESCRIBINGINFORMATIONforCANCIDAS-Merck.Availableonline:https://www.accessdata.fda.gov/
drugsatfda_docs/label/2021/021227Orig1s040lbl.pdf(accessedon17September2023).
4. Sinnollareddy,M.G.;Roberts,J.A.;Lipman,J.;Akova,M.;Bassetti,M.;DeWaele,J.J.;Kaukonen,K.M.;Koulenti,D.;Martin,C.;
Montravers,P.;etal.Pharmacokineticvariabilityandexposuresoffluconazole,anidulafungin,andcaspofungininintensivecare
unitpatients:DatafrommultinationalDefiningAntibioticLevelsinIntensivecareunit(DALI)patientsStudy.Crit.Care2015,19,
33.[CrossRef][PubMed]
5. vanderElst,K.C.;Veringa,A.;Zijlstra,J.G.;Beishuizen,A.;Klont,R.;Brummelhuis-Visser,P.;Uges,D.R.;Touw,D.J.;Kosterink,
J.G.;vanderWerf,T.S.;etal.LowCaspofunginExposureinPatientsinIntensiveCareUnits.Antimicrob.AgentsChemother.2017,
61,e01582-16.[CrossRef][PubMed]
6. vanVianen,W.;deMarie,S.;tenKate,M.T.;Mathot,R.A.;Bakker-Woudenberg,I.A.Caspofungin:Antifungalactivityinvitro,
pharmacokinetics,andeffectsonfungalloadandanimalsurvivalinneutropenicratswithinvasivepulmonaryaspergillosis.J.
Antimicrob.Chemother.2006,57,732–740.[CrossRef]
7. Ambrose, P.G.; Bhavnani, S.M.; Rubino, C.M.; Louie, A.; Gumbo, T.; Forrest, A.; Drusano, G.L. Pharmacokinetics-
pharmacodynamicsofantimicrobialtherapy:It’snotjustformiceanymore.Clin.Infect.Dis.2007,44,79–86.[CrossRef]
Pharmaceutics2024,16,819 22of23
8. Wiederhold,N.P.;Kontoyiannis,D.P.;Chi,J.;Prince,R.A.;Tam,V.H.;Lewis,R.E.Pharmacodynamicsofcaspofungininamurine
modelofinvasivepulmonaryaspergillosis:Evidenceofconcentration-dependentactivity. J.Infect. Dis. 2004,190,1464–1471.
[CrossRef]
9. Louie,A.;Deziel,M.;Liu,W.;Drusano,M.F.;Gumbo,T.;Drusano,G.L.Pharmacodynamicsofcaspofungininamurinemodelof
systemiccandidiasis: Importanceofpersistenceofcaspofunginintissuestounderstandingdrugactivity. Antimicrob. Agents
Chemother.2005,49,5058–5068.[CrossRef][PubMed]
10. Andes,D.;Diekema,D.J.;Pfaller,M.A.;Bohrmuller,J.;Marchillo,K.;Lepak,A.Invivocomparisonofthepharmacodynamic
targetsforechinocandindrugsagainstCandidaspecies.Antimicrob.AgentsChemother.2010,54,2497–2506.[CrossRef]
11. Borsuk-DeMoor,A.;Sysiak-Sławecka,J.;Rypulak,E.;Borys,M.;Piwowarczyk,P.;Raszewski,G.;Onichimowski,D.;Czuczwar,
M.; Wiczling, P. Nonstationary Pharmacokinetics of Caspofungin in ICU Patients. Antimicrob. Agents Chemother. 2020, 64,
e00345-20.[CrossRef]
12. Pérez-Pitarch,A.;Ferriols-Lisart,R.;Aguilar,G.;Ezquer-Garín,C.;Belda,F.J.;Guglieri-López,B.Dosingofcaspofunginbasedon
apharmacokinetic/pharmacodynamicindexforthetreatmentofinvasivefungalinfectionsincriticallyillpatientsoncontinuous
venovenoushaemodiafiltration.Int.J.Antimicrob.Agents2018,51,115–121.[CrossRef][PubMed]
13. Sheiner,L.B.;Beal,S.;Rosenberg,B.;Marathe,V.V.Forecastingindividualpharmacokinetics. Clin. Pharmacol. Ther. 1979,26,
294–305.[CrossRef][PubMed]
14. Page,M.J.; McKenzie,J.E.; Bossuyt,P.M.; Boutron,I.; Hoffmann,T.C.; Mulrow,C.D.; Shamseer,L.; Tetzlaff,J.M.; Akl,E.A.;
Brennan,S.E.;etal.ThePRISMA2020statement:Anupdatedguidelineforreportingsystematicreviews.BMJ2021,372,n71.
[CrossRef][PubMed]
15. Liu, X.; Ju, G.; Yang, W.; Chen, L.; Xu, N.; He, Q.; Zhu, X.; Ouyang, D. Escitalopram Personalized Dosing: A Population
PharmacokineticsRepositoryMethod.DrugDes.Devel.Ther.2023,17,2955–2967.[CrossRef][PubMed]
16. Jamsen, K.M.; McLeay, S.C.; Barras, M.A.; Green, B.Reportingapopulationpharmacokinetic-pharmacodynamicstudy: A
journal’sperspective.Clin.Pharmacokinet.2014,53,111–122.[CrossRef][PubMed]
17. Kanji,S.;Hayes,M.;Ling,A.;Shamseer,L.;Chant,C.;Edwards,D.J.;Edwards,S.;Ensom,M.H.;Foster,D.R.;Hardy,B.;etal.
ReportingGuidelinesforClinicalPharmacokineticStudies: TheClinPKStatement. Clin. Pharmacokinet. 2015, 54, 783–795.
[CrossRef][PubMed]
18. Fancher,K.M.;Sacco,A.J.;Gwin,R.C.;Gormley,L.K.;Mitchell,C.B.Comparisonoftwodifferentformulasforbodysurfacearea
inadultsatextremesofheightandweight.J.Oncol.Pharm.Pract.2016,22,690–695.[CrossRef][PubMed]
19. Li,Z.R.;Wang,C.Y.;Zhu,X.;Jiao,Z.PopulationPharmacokineticsofLevetiracetam:ASystematicReview.Clin.Pharmacokinet.
2021,60,305–318.[CrossRef]
20. Lewis,R.E.Currentconceptsinantifungalpharmacology.MayoClin.Proc.2011,86,805–817.[CrossRef]
21. Ernst,E.J.;Klepser,M.E.;Ernst,M.E.;Messer,S.A.;Pfaller,M.A.InvitropharmacodynamicpropertiesofMK-0991determinedby
time-killmethods.Diagn.Microbiol.Infect.Dis.1999,33,75–80.[CrossRef]
22. CLSI.PerformanceStandardsforAntifungalSusceptibilityTestingofYeasts;CLSI:Berwyn,PA,USA,2022.
23. Li,F.;Zhou,M.;Jiao,Z.;Zou,Z.;Yu,E.;He,Z.CaspofunginpharmacokineticsandprobabilityoftargetattainmentinICUpatients
inChina.J.Glob.Antimicrob.Resist.2021,25,238–263.[CrossRef][PubMed]
24. Mori, M.; Imaizumi, M.; Ishiwada, N.; Kaneko, T.; Goto, H.; Kato, K.; Hara, J.; Kosaka, Y.; Koike, K.; Kawamoto, H.; etal.
Pharmacokinetics,efficacy,andsafetyofcaspofungininJapanesepediatricpatientswithinvasivecandidiasisandinvasive
aspergillosis.J.Infect.Chemother.2015,21,421–426.[CrossRef][PubMed]
25. Niu,C.H.;Xu,H.;Gao,L.L.;Nie,Y.M.;Xing,L.P.;Yu,L.P.;Wu,S.L.;Wang,Y.PopulationPharmacokineticsofCaspofunginand
DosingOptimizationinChildrenwithAllogeneicHematopoieticStemCellTransplantation. Front. Pharmacol. 2020,11,184.
[CrossRef][PubMed]
26. Pressiat,C.;Ait-Ammar,N.;Daniel,M.;Hulin,A.;Botterel,F.;Levesque,E.Pharmacokinetics/PharmacodynamicsofCaspofungin
inPlasmaandPeritonealFluidofLiverTransplantRecipients. Antimicrob. AgentsChemother. 2022,66,e0118721. [CrossRef]
[PubMed]
27. Yang,X.M.;Leroux,S.;Storme,T.;Zhang,D.L.;deBeaumais,T.A.;Shi,H.Y.;Yang,Y.L.;Wang,X.L.;Zhao,W.;Jacqz-Aigrain,E.
BodySurfaceArea-BasedDosingRegimenofCaspofungininChildren:APopulationPharmacokineticsConfirmatoryStudy.
Antimicrob.AgentsChemother.2019,63,e00248-19.[CrossRef][PubMed]
28. Würthwein,G.;Cornely,O.A.;Trame,M.N.;Vehreschild,J.J.;Vehreschild,M.J.;Farowski,F.;Müller,C.;Boos,J.;Hempel,G.;
Hallek,M.;etal.PopulationpharmacokineticsofescalatingdosesofcaspofungininaphaseIIstudyofpatientswithinvasive
aspergillosis.Antimicrob.AgentsChemother.2013,57,1664–1671.[CrossRef][PubMed]
29. Wu,Z.;Lan,J.;Wang,X.;Wu,Y.;Yao,F.;Wang,Y.;Zhao,B.X.;Wang,Y.;Chen,J.;Chen,C.PopulationPharmacokineticsof
CaspofunginandDoseSimulationsinHeartTransplantRecipients.Antimicrob.AgentsChemother.2022,66,e0224921.[CrossRef]
[PubMed]
30. Wang,Q.;Zhang,Z.;Liu,D.;Chen,W.;Cui,G.;Li,P.;Zhang,X.;Li,M.;Zhan,Q.;Wang,C.PopulationPharmacokineticsof
CaspofunginamongExtracorporealMembraneOxygenationPatientsduringthePostoperativePeriodofLungTransplantation.
Antimicrob.AgentsChemother.2020,64,e00687-20.[CrossRef]
Pharmaceutics2024,16,819 23of23
31. Bailly,S.;Gautier-Veyret,E.;Lê,M.P.;Bouadma,L.;Andremont,O.;Neuville,M.;Mourvillier,B.;Sonneville,R.;Magalhaes,E.;
Lebut,J.;etal. ImpactofLoadingDoseofCaspofungininPharmacokinetic-PharmacodynamicTargetAttainmentforSevere
CandidiasisInfectionsinPatientsinIntensiveCareUnits: TheCASPOLOADStudy. Antimicrob. AgentsChemother. 2020,64,
e01545-20.[CrossRef]
32. Würthwein,G.;Young,C.;Lanvers-Kaminsky,C.;Hempel,G.;Trame,M.N.;Schwerdtfeger,R.;Ostermann,H.;Heinz,W.J.;
Cornely, O.A.; Kolve, H.; et al. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic
hematopoieticstemcellrecipients.Antimicrob.AgentsChemother.2012,56,536–543.[CrossRef]
33. Gastine,S.;Hempel,G.;Neely,M.N.;Walsh,T.J.;Groll,A.H.Pharmacokineticmodellingofcaspofungintodevelopanextended
dosingregimeninpaediatricpatients.J.Antimicrob.Chemother.2022,77,2209–2216.[CrossRef]
34. Yang,Q.;Zhang,T.;Zhang,Y.;Sun,D.;Zheng,X.;Du,Q.;Wang,X.;Cheng,X.;Xing,J.;Dong,Y.Therecommendeddosage
regimenforcaspofungininpatientswithhigherbodyweightorhypoalbuminaemiawillresultinlowexposure:Fiveyearsof
databasedonapopulationpharmacokineticmodelandMonte-Carlosimulations.Front.Pharmacol.2022,13,993330.[CrossRef]
[PubMed]
35. Sandhu,P.;Lee,W.;Xu,X.;Leake,B.F.;Yamazaki,M.;Stone,J.A.;Lin,J.H.;Pearson,P.G.;Kim,R.B.Hepaticuptakeofthenovel
antifungalagentcaspofungin.DrugMetab.Dispos.2005,33,676–682.[CrossRef][PubMed]
36. Stader, F.; Wuerthwein, G.; Groll, A.H.; Vehreschild, J.J.; Cornely, O.A.; Hempel, G.Physiology-basedpharmacokineticsof
caspofunginforadultsandpaediatrics.Pharm.Res.2015,32,2029–2037.[CrossRef][PubMed]
37. Walsh,T.J.;Adamson,P.C.;Seibel,N.L.;Flynn,P.M.;Neely,M.N.;Schwartz,C.;Shad,A.;Kaplan,S.L.;Roden,M.M.;Stone,J.A.;
etal.Pharmacokinetics,safety,andtolerabilityofcaspofungininchildrenandadolescents.Antimicrob.AgentsChemother.2005,49,
4536–4545.[CrossRef][PubMed]
38. Sáez-Llorens,X.;Macias,M.;Maiya,P.;Pineros,J.;Jafri,H.S.;Chatterjee,A.;Ruiz,G.;Raghavan,J.;Bradshaw,S.K.;Kartsonis,
N.A.;etal.Pharmacokineticsandsafetyofcaspofungininneonatesandinfantslessthan3monthsofage.Antimicrob.Agents
Chemother.2009,53,869–875.[CrossRef][PubMed]
39. Sinha,J.;Al-Sallami,H.S.;Duffull,S.B.ChoosingtheAllometricExponentinCovariateModelBuilding.Clin.Pharmacokinet.2019,
58,89–100.[CrossRef][PubMed]
40. Fortmann,I.; Hartz,A.; Paul,P.; Pulzer,F.; Müller,A.; Böttger,R.; Proquitté,H.; Dawczynski,K.; Simon,A.; Rupp,J.; etal.
AntifungalTreatmentandOutcomeinVeryLowBirthWeightInfants:APopulation-basedObservationalStudyoftheGerman
NeonatalNetwork.Pediatr.Infect.Dis.J.2018,37,1165–1171.[CrossRef]
41. Roch,A.;Woloch,C.;Blayac,D.;Solas,C.;Quaranta,S.;Mardelle,V.;Castanier,M.;Papazian,L.;Sampol-Manos,E.Effectoffluid
loadingduringhypovolaemicshockoncaspofunginpharmacokineticparametersinpig.Crit.Care2011,15,R219.[CrossRef]
42. Roberts, J.A.; Abdul-Aziz, M.H.; Lipman, J.; Mouton, J.W.; Vinks, A.A.; Felton, T.W.; Hope, W.W.; Farkas, A.; Neely, M.N.;
Schentag,J.J.;etal.Individualisedantibioticdosingforpatientswhoarecriticallyill:Challengesandpotentialsolutions.Lancet
Infect.Dis.2014,14,498–509.[CrossRef]
43. Gasperetti,T.;Welte,R.;Oberacher,H.;Marx,J.;Lorenz,I.;Schellongowski,P.;Staudinger,T.;Burgmann,K.;Eller,P.;Santner,T.;
etal.Penetrationofechinocandinsintowoundsecretionofcriticallyillpatients.Infection2021,49,747–755.[CrossRef][PubMed]
44. Betts, R.F.; Nucci, M.; Talwar, D.; Gareca, M.; Queiroz-Telles, F.; Bedimo, R.J.; Herbrecht, R.; Ruiz-Palacios, G.; Young, J.A.;
Baddley,J.W.;etal.AMulticenter,double-blindtrialofahigh-dosecaspofungintreatmentregimenversusastandardcaspofungin
treatmentregimenforadultpatientswithinvasivecandidiasis.Clin.Infect.Dis.2009,48,1676–1684.[CrossRef][PubMed]
45. Kurland,S.;Furebring,M.;Löwdin,E.;Eliasson,E.;Nielsen,E.I.;Sjölin,J.PharmacokineticsofCaspofungininCriticallyIll
PatientsinRelationtoLiverDysfunction: DifferentialImpactofPlasmaAlbuminandBilirubinLevels. Antimicrob. Agents
Chemother.2019,63,e02466-18.[CrossRef][PubMed]
46. Liu,X.;Ju,G.;Huang,X.;Yang,W.;Chen,L.;Li,C.;He,Q.;Xu,N.;Zhu,X.;Ouyang,D.Escitaloprampopulationpharmacokinetics
andremedialstrategiesbasedonCYP2C19phenotype.J.Affect.Disord.2024,346,64–74.[CrossRef]
47. Kurland,S.;Löwdin,E.;Furebring,M.;Shams,A.;Chryssanthou,E.;Lagerbäck,P.;Tängden,T.;Breuer,O.;Sjölin,J.Human
plasmaproteinlevelsaltertheinvitroantifungalactivityofcaspofungin:Anexplanationtotheeffectincriticallyill?Mycoses
2022,65,79–87.[CrossRef]
Disclaimer/Publisher’sNote: Thestatements, opinionsanddatacontainedinallpublicationsaresolelythoseoftheindividual
author(s)andcontributor(s)andnotofMDPIand/ortheeditor(s).MDPIand/ortheeditor(s)disclaimresponsibilityforanyinjuryto
peopleorpropertyresultingfromanyideas,methods,instructionsorproductsreferredtointhecontent.
Figure S1: The steady-state concentration-time profiles of piperacillin for (a) infants, (b) children,
and (c) adults when infused intermittently. The solid line represents median of the simulated
concentration-time profile. The light shadows represent the 10th-90th percentiles of the simulated
concentration-time profiles. All virtual patients were assumed to be male received caspofungin at a
dose of 70mg on the first day, followed by 50 mg once a day as infusion for 1h for adults and
70mg/m2 on the first day, followed by 50 mg/m2 once a day as infusion for 1h for infants and
children.
Section Suggested contents
Introduction Motivation for and objective(s) of the pharmacometrics research
Methods Sufficient information for the general reader to repeat the study:
Ethics approval, Study population,
Dosing, Sampling schedule
Analytical methods and lower limit of quantification
Pharmacokinetic or pharmacokinetic
pharmacodynamic modelling strategy:
– Candidate structural models
– Distribution of individual model parameters
– Residual error structure
– Methods for handling missing data
– Methods for base model determination
– Methods for base model evaluation
– Covariate analysis strategy
– Methods for final model evaluation
– Software package(s) used for the analysis
– Estimation method(s) used
Results Numbers of individuals and observations included in the analysis
Table of patient demographic and clinical variables
Plot of concentrations versus time and/or effects versus
concentrations
Summary of the model-building process and the derived final
model Schematic of the final model, Table of the final model
parameters, Final model evaluation plots
Discussion Highlight what the study achieved, implications of the work
suggestions for future work and limitations of the study
Conclusion Briefly answer questions posed by the objectives
Figure S2：Check List
The search terms utilized for compiling the model library:
Pubmed: (“Caspofungun" or “cancidas" or “MK 0991" or “L 743,872" ) AND ("population
pharmacokinetic" or "nonlinear mixed effect model" or "NONMEM" or "Pmetrics" or
"WINNONMIX" or "ADAPT" or "P-PHARM" or "nlmixr" or "NLME" or "USC*PACK" or
"MONOLIX")
Scopus: (TITLE-ABS-KEY(caspofungin) OR TITLE-ABS-KEY(cancidas) OR TITLE-
ABS-KEY(mk 0991) OR TITLE-ABS-KEY(l 743872)) AND (TITLE-ABS-
KEY(populationANDpharmacokinetics) OR TITLE-ABS-
KEY(nonlinear AND mixed AND effect AND model) OR TITLE-ABS-
KEY(nonmem) OR TITLE-ABS-KEY(pmetrics) OR TITLE-ABS-
KEY(winnonmix) OR TITLE-ABS-KEY(adapt) OR TITLE-ABS-KEY(p-
pharm) OR TITLE-ABS-KEY(nlmixr) OR TITLE-ABS-KEY(nlme) OR TITLE-ABS-
KEY(monolix))
Web of Science: (TS=(Caspofungin) OR TS=(cancidas) OR TS=(MK 0991) OR TS=(L743,872))
AND (TS=(population pharmacokinetic) OR TS=(nonlinear mixed effect model)OR
TS=(NONMEM) OR TS=(Pmetrics) OR TS=(WINNONMIX) OR TS=(ADAPT) OR TS=(P-
PHARM) OR TS=(nlmixr) OR TS=(NLME) OR TS=(MONOLIX))
Embase: (Caspofungin or cancidas or “MK 0991” or L43,872) and (population pharmacokinetics
or nonlinear mixed effect model or NONMEM or Pmetrics or WINNONMEX or ADAPT or P-
PHARM or nlmixr or USC*PACK or MONOLIX)
Code:
#AiM: Establish a model repository of parametric PPK models for Caspofungin using rxode2
#Author:Nuo Xu
#Update data:2022/11/08
#Connect:nuoxu22@m.edu.cn
rm(list=ls())
#set working directory to current folder
curr.dir<-dirname(rstudioapi::getActiveDocumentContext()$path)
setwd(curr.dir)
# create the result folder
output_dir <- "Result"
if (!file.exists(output_dir)) {dir.create(output_dir)}
library(tidyverse) # for data visualization and manipulation
library(rxode2) # for simulation
library(patchwork)
library(cowplot)
#-----------------------------------------
#----------Adults 70KG 40Y -------------------------
#-----------------------------------------
# Define the 2-comp model,model info
# CL（L/h）=0.462
# V1（L） =8.33
# Q (L/h) =1.25
# V2 (L) =3.59
# IIV(CL) =25%
# IIV(V1) =29%
# Proportional error=0.21
# BW(kg)
# Typical population:
# Adults Allogeneic Hematopoietic Stem Cell Recipients
# age : 40 years old
# BW : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(123456)
# 2-comp model
mod1 <- RxODE({
CL = TVCL*exp(eta.CL);
V1 = TVV1*exp(eta.V1);
Q = TVQ;
V2 = TVV2;
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Adults
# Define typical patient: adults
BW <- 70 # kg
AGE <- 40 # years old
# Define fixed effect parameters
theta1<- c(TVCL=0.462, TVV1=8.33, TVQ=1.25, TVV2=3.59)
# Define between subject variability
omega1 <- lotri(eta.CL ~ 0.25^2, eta.V1 ~ 0.29^2)
# Define unexplained variability
sigma1 <- lotri(prop.err.sd ~ 0.21^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev1 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim1 <- rxSolve(mod1,theta1,ev1,omega=omega1,sigma=sigma1,nSub=1000)
# Concentration-Time plot
pk_CAS1 <- sim1 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat1 <- pk_CAS1 %>%
mutate(study="Würthwein et al.(2011)",
drug="CAS",
pop="Adult")
# 2----Würthwein et al.(2013)----
# Define the 2-comp model,model info
# CL = 0.411*(1+0.0102*(BW-76)) (L/h)
# V1 = 5.85*(1+0.0102*(BW-76)) (L)
# Q = 0.843 (L/h)
# V2 = 6.53 (L)
# IIV(CV%): CL = 0.285, V1 = 0.288, V2 = 0.668
# 0.285=sqrt(exp(omega^2)-1)
# omega^2=log(0.285^2+1)=0.0781
# IOV(CV%): CL = 0.16
# prop.err = 0.143
# Correlation for CL-V1: 0.802
# omega1,2=omega2,1/(sqrt(omega1,1^2)*sqrt(omega2,2^2))
# omega2,1=0.802*sqrt(0.0781)*sqrt(0.079) =0.06299607
# omega2,1^2=0.003968505=0.00397
# Typical population:
# Adults Allogeneic Hematopoietic Stem Cell Recipients
# BW : 70kg
# age : 40 years old
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(1234567)
pop_par <- c(0.411, # (L/h), CL
5.85, # (L), V1
0.843, # (L/h), Q
6.53) # (L), V2
eta2.cl <- 0.0781 # omega^2=log(0.285^2+1)
eta2.v1 <- 0.0797 # omega^2=log(0.288^2+1)
eta2.v2 <- 0.3690 # omega^2=log(0.668^2+1)
iov2.cl <- 0.0253 # omega^2=log(0.16^2+1)
cov2.cl_v1 <- 0.06327 # 0.802=omega2,1/(sqrt(omega1,1^2)*sqrt(omega2,2^2))
prop.err <- 0.143
# dose regimen
# an initial dose of 70 mg followed by
# a maintenance dose of 50 mg/24 h infused
# over a 1-hour period
intialdose <- 70 # mg
maintaindose <- 50 # mg
dur <- 1 # 1 h
dose_days <- 4 # 4 days
interval <- 24 # 24 h
nsub <- 1000
WT <- 70
# 1. Create virtual patients
covar <- data.frame(id = c(1:nsub),
WT = WT)
# 2. Define PPK model of Caspofungin
# a 2-comp model with the first order elimination
mod2 <- RxODE({
CL = TVCL*exp(eta.CL+iov.CL1*occ1+iov.CL2*occ2+iov.CL3*occ3+iov.CL4*occ4);
V1 = TVV1*exp(eta.V1);
Q = TVQ;
V2 = TVV2*exp(eta.V2);
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd);
})
# Define fixed effect parameters
theta2 <- c(TVCL=pop_par[1]*(1+0.0102*(WT-76)),
TVV1=pop_par[2]*(1+0.0102*(WT-76)),
TVQ=pop_par[3],
TVV2=pop_par[4])
# Define between subject variability
omega2 <- lotri(lotri(eta.CL + eta.V1 + eta.V2 ~
c(eta2.cl, # IIV CL
cov2.cl_v1, eta2.v1, # IIV V1
0, 0, eta2.v2)) , # IIV V2
lotri(iov.CL1 ~ iov2.cl), # IOV CL
lotri(iov.CL2 ~ iov2.cl),
lotri(iov.CL3 ~ iov2.cl),
lotri(iov.CL4 ~ iov2.cl))
# Define unexplained variability
sigma2 <- lotri(prop.err.sd ~ prop.err^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# define event record
ev2 <- et(amount.units = "mg", time.units = "hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1)) %>%
mutate(occ=cumsum(!is.na(amt))) %>%
mutate(occ1=case_when(occ==1 ~ 1,
TRUE ~ 0),
occ2=case_when(occ==2 ~ 1,
TRUE ~ 0),
occ3=case_when(occ==3 ~ 1,
TRUE ~ 0),
occ4=case_when(occ==4 ~ 1,
TRUE ~ 0)) %>%
as.data.frame() %>%
as_tibble
sim2 <- rxSolve(mod2, theta2, ev2, omega=omega2, sigma=sigma2,nSub=1000)
# Concentration-Time plot
pk_CAS2 <- sim2 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat2 <- pk_CAS2 %>%
mutate(study="Würthwein et al.(2013)",
drug="CAS",
pop="Adult")
# 3---- Pérez-Pitarch et al. (2018)----
# Define the 2-comp model,model info
# kel（h-1）=0.0899（6%）
# Vc（L） =6.46（7%）
# k12（h-1）=0.494（13%）
# k12（h-1）=0.392（12%）
# ETA(kel) = 0.0140
# ETA(Vc) = 0.0460
# Additive error=0.0941（6%）
# WT(kg)
# Typical population:
# Adults
# AGE : 40 years old
# BW : 70 kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(12345678)
# 2-comp model
mod3 <- RxODE({
ke = TVke*exp(eta.ke);
V1 = TVV1*exp(eta.V1);
k12 = TVk12;
k21 = TVk21;
CL = V1*ke;
V2 = V1*k12/k21;
Q = V1*k12;
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1+add.err
})
# Adults
# Define typical patient: adults
BW <- 70 # kg
AGE <- 40 # years old
# Define fixed effect parameters
theta3<- c( TVke =0.0899,
TVV1 =6.46,
TVk12 =0.494,
TVk21 =0.392)
# Define between subject variability
omega3 <- lotri(eta.ke ~ 0.0140, eta.V1 ~ 0.0460)
# Define unexplained variability
sigma3 <- lotri(add.err ~ 0.0941)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev3 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim3 <- rxSolve(mod3,theta3,ev3,omega=omega3,sigma=sigma3,nSub=1000)
# Concentration-Time plot
pk_CAS3 <- sim3 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat3 <- pk_CAS3 %>%
mutate(study="Pérez-Pitarch et al. (2018)",
drug="CAS",
pop="Adult")
# 4----Wang et al.(2020)-----
# Define the 2-comp model,model info
# CL(L/h) =0.21*(OPT/5)^1.3(8%)
# Vc(L) =(2.21+SEX*0.62)*(OPT/5)^0.93(5%)
# Vp(L) =2.87(16%)
# Q(L/h) =0.84*(SOFA/7)^1.98(11%)
# IIV(CL) =0.04(21.3%)
# IIV(Vc) =0.01(15.5%)
# IIV(Vp) =0.23(21.2%)
# add.error=0.73
# OPT : operative time(h)
# SEX : male,SEX=1;female,SEX=0
# SOFA: score for organ failure
# Typical population:
# Adults
# male SEX=1
# age : 40 years old
# OPT : 4.0h
# WT : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(123456789)
# 2-comp model
mod4 <- RxODE({
CL = TVCL*exp(iiv.CL);
V1 = TVV1*exp(iiv.V1);
Q = TVQ;
V2 = TVV2*exp(iiv.V2);
C1 = centr/V1;
C2 = peri/V2
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1 + add.err.sd
})
# Adults
# Define typical patient: adults
OPT <- 5 # h
SEX <- 1 # male
# Define fixed effect parameters
theta4<- c(TVCL=0.21*(OPT/5)^1.3^(0.04),
TVV1=(2.21+SEX*0.62)*(OPT/5)^0.93^(0.01),
TVQ =0.84,
TVV2=2.87)
# Define between subject variability
omega4 <- lotri(iiv.CL ~ 0.04, iiv.V1 ~ 0.01,iiv.V2 ~ 0.23)
# Define unexplained variability
sigma4 <- lotri(add.err.sd ~ 0.73)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev4 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim4 <- rxSolve(mod4,theta4,ev4,omega=omega4,sigma=sigma4,nSub=1000)
# Concentration-Time plot
pk_CAS4 <- sim4 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat4 <- pk_CAS4 %>%
mutate(study="Wang et al.(2020)",
drug="CAS",
pop="Adult")
# 5----Bailly et al.(2020)----
# Define the 2-comp model,model info
# CL(L/h) =0.98(13%)
# V1(L) =9.01(13.4%)
# V2(L) =11.9(24%)
# Q(L/h) =5.12(26.7%)
# IIV(CL) =0.423(23.1%)
# IIV(V1) =0.426(24.5%)
# IIV(V2) =0.772
# IIV(Q) =0.799
# prop error=0.122
# Typical population:
# Adults
# age : 40 years old
# BW : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(123456789)
# 2-comp model
mod5 <- RxODE({
CL = TVCL*exp(iiv.CL);
V1 = TVV1*exp(iiv.V1);
Q = TVQ*exp(iiv.Q);
V2 = TVV2*exp(iiv.V2);
C1 = centr/V1;
C2 = peri/V2
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Adults
# Define typical patient: ICU patients
# BW : 70kg
# Age: 40 years old
# Define fixed effect parameters
theta5<- c(TVCL =0.98,
TVV1 =9.01,
TVQ =5.12,
TVV2 =11.9)
# Define between subject variability
omega5 <- lotri(iiv.CL ~ 0.423^2, iiv.V1 ~ 0.426^2,iiv.V2 ~ 0.772^2,iiv.Q ~ 0.799^2)
# Define unexplained variability
sigma5 <- lotri(prop.err.sd ~ 0.122^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev5 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim5 <- rxSolve(mod5,theta5,ev5,omega=omega5,sigma=sigma5,nSub=1000)
# Concentration-Time plot
pk_CAS5 <- sim5 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat5 <- pk_CAS5 %>%
mutate(study="Bailly et al.(2020)",
drug="CAS",
pop="Adult")
# 6----Li et al.(2021)----
# Define the 2-comp model,model info
# CL（L/h）=0.323（11%）
# V1（L） =6.77(10%)
# Q (L/h) =0.923(32%)
# V2 (L) =4.12(25%)
#Effect of weight on V1 =1.08(24%)
#Effect of ALB on CL =1.27(30%)
#Effect of TBIL(≤22μmol/L) on CL =0.89(12%)
#Effect of TBIL(>22μmol/L) on CL =0.265(32%)
# CL (L/h) = 0.323×0.89× (35/ALB)^1.27 (if TBIL ≤ 22 μmol/L)
# CL (L/h) = 0.323× (35/ALB)^1.27×(TBIL/22)^0.265 (if TBIL > 22 μmol/L)
# Vc (L) = 6.77× (WT/70)^1.08
# Q (L/h) = 0.923
# Vp (L) = 4.58
# IIV(CL) =0.224（18%）
# Proportional error=0.24（21%）
# BW(kg)
# Typical population:
# Adults Allogeneic Hematopoietic Stem Cell Recipients
# age : 40 years old
# BW : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(123456)
# 2-comp model
mod6 <- RxODE({
CL = TVCL*exp(iiv.CL);
V1 = TVV1;
Q = TVQ;
V2 = TVV2;
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Adults
# Define typical patient: adults
BW <- 70 # kg
ALB <- 35
TBIL<- 22 #μmol/L
# Define fixed effect parameters
theta6<- c(TVCL =0.323*0.89* (35/ALB)^1.27 ,
TVV1 =6.77*(BW/70)^1.08,
TVQ =0.923,
TVV2 =4.58)
# Define between subject variability
omega6 <- lotri(iiv.CL ~ 0.224^2)
# Define unexplained variability
sigma6 <- lotri(prop.err.sd ~ 0.24^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev6 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim6 <- rxSolve(mod6,theta6,ev6,omega=omega6,sigma=sigma6,nSub=1000)
# Concentration-Time plot
pk_CAS6 <- sim6 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat6 <- pk_CAS6 %>%
mutate(study="Li et al.(2021)",
drug="CAS",
pop="Adult")
# 7----Borsuk-De Moor et al.(2021)-----
# Define the 2-comp model,model info
# TVCL(L/h) =0.563(6.7%)
# TVV1(L) =6.04(7.0 %)
# TVV2(L) =5.13(13.7%)
# TVQ(L/h) =1.31(15.7%)
# CL = TVCL*(BW/70)^0.75
# V = TVV*(BW/70)^1
# IIV(CL) =0.247(27.3%)
# IIV(V1) =0.286.0(39.6%)
# IIV(V2) =0.494(37.1%)
# IIV(Q) =0 FIX
# prop error = 0.199
# Typical population:
# Adults
# age : 40 years old
# BW : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(123456)
# 2-comp model
mod7 <- RxODE({
CL = TVCL*exp(iiv.CL);
V1 = TVV1*exp(iiv.V1);
Q = TVQ;
V2 = TVV2*exp(iiv.V2);
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Adults
# Define typical patient: adults
BW <- 70 # kg
AGE <- 40 # years old
# Define fixed effect parameters
theta7<- c(TVCL =0.563*(BW/70)^0.75,
TVV1 =6.04*(BW/70)^1,
TVV2 =5.13*(BW/70)^1,
TVQ =1.31)
# Define between subject variability
omega7 <- lotri(iiv.CL + iiv.V1 ~ C(0.247^2,
0.868 ,0.282^2),
iiv.V2 ~ 0.494^2)
# Define unexplained variability
sigma7 <- lotri(prop.err.sd ~ 0.199^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev7 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim7 <- rxSolve(mod7,theta7,ev7,omega=omega7,sigma=sigma7,nSub=1000)
# Concentration-Time plot
pk_CAS7 <- sim7 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat7 <- pk_CAS7 %>%
mutate(study="Moor et al.(2021)",
drug="CAS",
pop="Adult")
# 8----Wu et al.(2022)-----
# Define the 2-comp model,model info
# CL(L/h) =0.385(5%)
# Vc(L) =4.27(12%)
# Q(L/h) =2.85(11%)
# Vp(L) =6.01(13%)
# CL = TVCL* exp(eta.CL) *(ALB/37.42)^(-1.01)
# V1 = TVV1* exp(eta.V1)
# Q = TVQ * exp(eta.Q)
# V2 = TVV2* exp(eta.V2)
# IIV(CL) =0.335
# IIV(V1) =0.675
# IIV(Q) =0 FIX
# IIV(V2) =0.477
# error=0.134
# additive error=0.213
# Typical population:
# Adults : Heart transplantation
# age : 40 years old
# BW : 70kg
# ALB level : 37.42 g/L
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(12345)
# 2-comp model
mod8 <- RxODE({
CL = TVCL* exp(iiv.CL)
V1 = TVV1* exp(iiv.V1)
Q = TVQ
V2 = TVV2* exp(iiv.V2)
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd) + add.err.sd
})
# Define typical patient: adults
BW <- 70 # kg
ALB <- 37.42 # g/L
# Define fixed effect parameters
theta8<- c(TVCL =0.385*(ALB/37.42)^(-1.01),
TVV1 =4.27,
TVV2 =6.01,
TVQ =2.85)
# Define between subject variability
omega8 <- lotri(iiv.CL ~ 0.335^2,iiv.V1 ~ 0.675^2 ,iiv.V2 ~ 0.477^2)
# Define unexplained variability
sigma8 <- lotri(prop.err.sd ~ 0.134^2, add.err.sd ~ 0.213)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev8 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim8 <- rxSolve(mod8,theta8,ev8,omega=omega8,sigma=sigma8,nSub=1000)
# Concentration-Time plot
pk_CAS8 <- sim8 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat8 <- pk_CAS8 %>%
mutate(study="Wu et al.(2022)",
drug="CAS",
pop="Adult")
# 9----Pressiat et al.(2022)-----
# Define the 2-comp model,model info
# CL(L/h) =0.38(8.16%)
# V1(L) =6.24(15.8%)
# Q(L/h) =2.58(0.2%)
# V2(L) =6.44(28.5%)
# IIV(CL) =0.33(18.6%)
# IIV(V1) =0.59(21.6%)
# IIV(V2) =1.07(21.9%)
# prop error=0.36(4.4%)
# Typical population:
# Adults : Liver Transplant Recipients
# age : 40 years old
# BW : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(12345)
rxSetseed(12345)
# 2-comp model
mod9 <- RxODE({
CL = TVCL* exp(iiv.CL)
V1 = TVV1* exp(iiv.V1)
Q = TVQ
V2 = TVV2* exp(iiv.V2)
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Define fixed effect parameters
theta9<- c(TVCL = 0.38,
TVV1 = 6.24,
TVV2 = 6.44,
TVQ = 2.58)
# Define between subject variability
omega9 <- lotri(iiv.CL ~ 0.33^2,iiv.V1 ~ 0.59^2 ,iiv.V2 ~ 1.07^2)
# Define unexplained variability
sigma9<- lotri(prop.err.sd ~ 0.36)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev9 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim9 <- rxSolve(mod9,theta9,ev9,omega=omega9,sigma=sigma9,nSub=1000)
# Concentration-Time plot
pk_CAS9 <- sim9 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat9 <- pk_CAS9 %>%
mutate(study="Pressiat et al.(2022)",
drug="CAS",
pop="Adult")
# 15----Yang et al.(2022)-----
# Define the 1-comp model,model info
# CL(L/h) =0.32*(1+0.46*ALB*)*(1+0.98*WT*)
# V(L) ==13.31*(1+0.49*ALB*)*(1+0.24*WT*)
# ALB*=1, ALB<35 g/L;
# ALB*=0, ALB≥35 g/L;
# WT*=1, WT≥70 kg,
# WT*=0, WT< 70 kg)
# WT*=1, ALB*=0
# CL(L/h) =0.32*(1+0.98)
# V(L) ==13.31*(1+0.24)
# IIV(CL) =0.292
# IIV(V1) =0.592
# prop error=19.3
# Typical population:
# Adultsye
# age : 40 years old
# BW : 70kg
# Dose: 70 mg on day 1,followed by 50 mg QD,Infusion for 1h
set.seed(12345)
rxSetseed(12345)
# 2-comp model
mod15 <- RxODE({
CL =TVCL*exp(iiv.CL); #a variable in the model.
V1 =TVV1*exp(iiv.V1);
conc=centr/V1;
d/dt(centr)=-CL*conc; #central
cp=conc*(1+prop.err.sd)
})
# Define fixed effect parameters
theta15<- c(TVCL = 0.6336,
TVV1 = 16.5044)
# Define between subject variability
omega15 <- lotri(iiv.CL ~ 0.292^2,iiv.V1 ~ 0.592^2)
# Define unexplained variability
sigma15<- lotri(prop.err.sd ~ 0.193)
# DOSE of CAS(iv)
dose_cas_day1 <-70 # mg 1-h infusion
dose_cas_later<-50 # mg 1-h infusion
# Define event record
ev15 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim15 <- rxSolve(mod15,theta15,ev15,omega=omega15,sigma=sigma15,nSub=1000)
# Concentration-Time plot
pk_CAS15 <- sim15 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat15 <- pk_CAS15 %>%
mutate(study="Yang et al.(2022)",
drug="CAS",
pop="Adult")
#----select data----
dat1 <- dat1 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat2 <- dat2 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat3 <- dat3 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat4 <- dat4 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat5 <- dat5 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat6 <- dat6 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat7 <- dat7 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat8 <- dat8 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat9 <- dat9 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat15 <- dat15 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
#----combine the plots (adults)----
# combine data
dat_cas_adult <- dat1 %>%
bind_rows(dat2) %>%
bind_rows(dat3) %>%
bind_rows(dat4) %>%
bind_rows(dat5) %>%
bind_rows(dat6) %>%
bind_rows(dat7) %>%
bind_rows(dat8) %>%
bind_rows(dat9) %>%
bind_rows(dat15)
# arrange by levels
dat_cas_adult$study <- factor(dat_cas_adult$study, levels = c("Würthwein et al.(2011)",
"Würthwein et
al.(2013)",
"Pérez-Pitarch et al.
(2018)",
"Wang et al.(2020)",
"Bailly et al.(2020)",
"Li et al.(2021)",
"Moor et al.(2021)",
"Wu et al.(2022)",
"Pressiat et
al.(2022)",
"Yang et al.(2022)"))
# change the label names
labelname1 <- c( "Würthwein et al.(2011)" ="Würthwein (2011)" ,
"Würthwein et al.(2013)" ="Würthwein (2013)" ,
"Pérez-Pitarch et al. (2018)" ="Pérez-Pitarch (2018)" ,
"Wang et al.(2020)" ="Wang (2020)" ,
"Bailly et al.(2020)" ="Bailly (2020)" ,
"Li et al.(2021)" = "Li (2021)" ,
"Moor et al.(2021)" = "Moor (2021)",
"Wu et al.(2022)" = "Wu (2022)" ,
"Pressiat et al.(2022)" = "Pressiat (2022)",
"Yang et al.(2022)" = "Yang (2022)")
pl1 <- dat_cas_adult %>%
mutate(lowconc=lowconc/70,
medconc=medconc/70,
highconc=highconc/70)%>%
ggplot(mapping=aes(x=tald, y=medconc)) +
geom_line(size=1.5, color="#003B8E") +
geom_ribbon(aes(x=tald,ymin=lowconc,ymax=highconc), fill = "#003B8E",alpha=0.2) +
theme_bw(base_size = 30) +
facet_wrap(~study, ncol = 5,
labeller = labeller(study=as_labeller(labelname1)),
scales="free") +
scale_x_continuous("Time (h)", limits = c(0,24.1), breaks = c(0,4,8,12,16,20,24)) +
scale_y_continuous("Concentration (mg/L/kg)") +
coord_cartesian(ylim = c(0,0.4)) +
ggtitle("c Adults: 70 kg, 40-year-old") +
theme (legend.position = "none",
plot.background = element_rect(fill = 'white'),
panel.grid.minor = element_blank(),
panel.grid.major = element_blank(),
plot.title = element_text(hjust = 0,
size = 30),
strip.background = element_rect(fill = "#CCD8E8"))
#export picture
jpeg(filename = paste0(output_dir, "/Caspofungin_Adult_plot2.jpg"), width=9000, height=4000,
res=300)
print(pl1)
dev.off()
dat_cas_adult2 <- dat1 %>%
bind_rows(dat2) %>%
bind_rows(dat3) %>%
bind_rows(dat5) %>%
bind_rows(dat6) %>%
bind_rows(dat7) %>%
bind_rows(dat8) %>%
bind_rows(dat9)
# change the label names
labelname4 <- c( "Würthwein et al.(2011)" ="Würthwein (2011)" ,
"Würthwein et al.(2013)" ="Würthwein (2013)" ,
"Pérez-Pitarch et al. (2018)" ="Alejandro (2018)" ,
"Bailly et al.(2020)" ="Bailly (2020)" ,
"Li et al.(2021)" = "Li (2021)" ,
"Moor et al.(2021)" = "Moor (2021)",
"Wu et al.(2022)" = "Wu (2022)" ,
"Pressiat et al.(2022)" ="Pressiat (2022)")
pl2 <- dat_cas_adult2 %>%
ggplot(mapping=aes(x=tald, y=medconc)) +
geom_line(size=1.5, color="#003B8E") +
geom_ribbon(aes(x=tald,ymin=lowconc,ymax=highconc), fill = "#003B8E",alpha=0.2) +
theme_bw(base_size = 30) +
facet_wrap(~study, ncol = 4,
labeller = labeller(study=as_labeller(labelname4)),
scales="free") +
scale_x_continuous("Time (h)", limits = c(0,24.1), breaks = c(0,4,8,12,16,20,24)) +
scale_y_continuous("Concentration (mg/L)") +
coord_cartesian(ylim = c(0,20)) +
ggtitle("c Adults: 70 kg, 40-year-old") +
theme (legend.position = "none",
plot.background = element_rect(fill = 'white'),
panel.grid.minor = element_blank(),
panel.grid.major = element_blank(),
plot.title = element_text(hjust = 0,
size = 30),
strip.background = element_rect(fill = "#CCD8E8"))
#export picture
jpeg(filename = paste0(output_dir, "/Caspofungin_Adult_plot_ref.jpg"), width=9000, height=4000,
res=300)
print(pl2)
dev.off()
#-----------------------------------------
#-----Children 20KG 6Y 100cm BSA 0.79---------
#-----------------------------------------
# 10----Yang et al.(2019)----
# Define the 2-comp model,model info
# CL(L/h) = 0.165
# V1(L) = 1.730
# Q(L/h) = 0.351
# V2(L) = 0.943
# FBSA-CL = (BSA/0.79)^1.3
# FBSA-V1 = (BSA/0.79)^1.5
# CL = TVCL*(BSA/0.79)^1.3*exp(iiv.CL)
# V1 = TVV1*(BSA/0.79)^1.5
# Q = TVQ* exp(iiv.Q)
# V2 = TVV2 × exp(iiv.V2)
# IIV(CL) =0.242(21.0%)
# IIV(Q) =1.616(90.0%)
# IIV(V2) =0.766(71.6%)
# Proportional error=0.196
# BSA,body surface area(m^2)
# Typical population:
# Children Allogeneic Hematopoietic Stem Cell Recipients
# age : 6 years old
# BW : 20kg
# HT : 100cm
# BSA : 0.79m^2
# Dose: 70 mg/m^2 on day 1,followed by 50 mg/m^2 QD,Infusion for 1h
set.seed(123456789)
# 2-comp model
mod10 <- RxODE({
CL = TVCL*exp(iiv.CL);
V1 = TVV1;
Q = TVQ*exp(iiv.Q);
V2 = TVV2*exp(iiv.V2);
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Adults
# Define typical patient: adults
BSA <- 0.79 # m^2
# Define fixed effect parameters
theta10<- c(TVCL =0.165*(BSA/0.79)^1.3,
TVV1 =1.73*(BSA/0.79)^1.5,
TVQ =0.351,
TVV2 =0.943)
# Define between subject variability
omega10 <- lotri(iiv.CL ~ 0.242^2,
iiv.Q ~ 1.616^2,
iiv.V2 ~ 0.766^2 )
# Define unexplained variability
sigma10 <- lotri(prop.err.sd ~ 0.196)
# DOSE of CAS(iv)
dose_cas_day1 <-70*BSA # mg 1-h infusion
dose_cas_later<-50*BSA # mg 1-h infusion
# Define event record
ev10 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim10 <- rxSolve(mod10,theta10,ev10,omega=omega10,sigma=sigma10,nSub=1000)
# Concentration-Time plot
pk_CAS10 <- sim10 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat10 <- pk_CAS10 %>%
mutate(study="Yang et al.(2019)",
drug="CAS",
pop="Child")
# 11----Niu et al.(2020)------
# Define the 1-comp model,model info
# TVCL(L/h) =0.14(8.50%)
# TVVd(L) =1.36(11.8 %)
# CL(L/h) =0.14*(BSA/0.79)^0.89*(InAST/3.38)^(-0.23)
# Vd(L) =1.36*(BSA/0.79)
# IIV(CL) =33.3%
# IIV(Vd) =32.9%
# prop error=0.266
# Typical population:
# Children With Allogeneic Hematopoietic Stem Cell Transplantation
# age : 6 years old
# BSA : 0.79m^2
# AST : 3.38
# BW : 20kg
# Dose: 70 mg/m^2 on day 1,followed by 50 mg/m^2 QD,Infusion for 1h
set.seed(1234567898)
# 1-comp model
mod11 <- RxODE({
CL =TVCL*exp(iiv.CL); #a variable in the model.
Vd =TVVd*exp(iiv.Vd);
conc=centr/Vd;
d/dt(centr)=-CL*conc; #central
cp=conc*(1+prop.err.sd)
})
# Define typical patient:
# Children With Allogeneic Hematopoietic Stem Cell Transplantation
# Age : 10 years old
# BW : 30kg
# BSA : 0.79 m^2
# InAST: 3.38
BSA <- 0.79
InAST<- 3.38
# Define fixed effect parameters
theta11<- c(TVCL =0.14*(BSA/0.79)^0.89*(InAST/3.38)^(-0.23),
TVVd =1.36*(BSA/0.79))
# Define between subject variability
omega11 <- lotri(iiv.CL ~ 0.333^2, iiv.Vd ~ 0.329^2)
# Define unexplained variability
sigma11 <- lotri(prop.err.sd ~ 0.266^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70*BSA # mg 1-h infusion
dose_cas_later<-50*BSA # mg 1-h infusion
# Define event record
ev11 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim11 <- rxSolve(mod11,theta11,ev11,omega=omega11,sigma=sigma11,nSub=1000)
# Concentration-Time plot
pk_CAS11 <- sim11 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat11 <- pk_CAS11 %>%
mutate(study="Niu et al.(2020)",
drug="CAS",
pop="Child")
# 12----Gastine et al.(2022)-----
# Define the 2-comp model,model info
# CL(L/h/70kg) = 0.790
# V1(L/70kg) = 7.75
# Q(L/h/70kg) = 1.2
# V2(L/70kg) = 5.29
# IIV(CL) = 0.275
# IIV(V1) = 0.315
# IIV(V2) = 0.151
# IOV(CL) = 0.172
# Proportional error=0.194
# Typical population:
# Children paediatric patients
# age : 6 years old
# BW : 20kg
# BSA : 0.79m^2
# Dose: 70 mg/m^2 on day 1,followed by 50 mg/m^2 QD,Infusion for 1h
set.seed(123456789)
# 2-comp model
mod12 <- RxODE({
CL = TVCL*exp(iiv.CL);
V1 = TVV1*exp(iiv.V1);
Q = TVQ;
V2 = TVV2*exp(iiv.V2);
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Define typical patient:
# children
# BW :30 kg
BW <- 20
BSA<- 0.79
# Define fixed effect parameters
theta12<- c(TVCL =0.79*(BW/70),
TVV1 =7.75*(BW/70),
TVQ =1.2*(BW/70),
TVV2 =5.29*(BW/70))
# Define between subject variability
omega12 <- lotri(iiv.CL ~ 0.275^2,
iiv.V1 ~ 0.315^2,
iiv.V2 ~ 0.151^2)
# Define unexplained variability
sigma12 <- lotri(prop.err.sd ~ 0.194^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70*BSA # mg 1-h infusion
dose_cas_later<-50*BSA # mg 1-h infusion
# Define event record
ev12 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim12 <- rxSolve(mod12,theta12,ev12,omega=omega12,sigma=sigma12,nSub=1000)
# Concentration-Time plot
pk_CAS12 <- sim12 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat12 <- pk_CAS12 %>%
mutate(study="Gastine et al.(2022)",
drug="CAS",
pop="Child")
#----plot_children-----
dat10 <- dat10 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat11 <- dat11 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
dat12 <- dat12 %>%
select(tald,lowconc,medconc,highconc,study,drug,pop)
# combine data
dat_cas_child <- dat10 %>%
bind_rows(dat11) %>%
bind_rows(dat12)
# arrange by levels
dat_cas_child$study <- factor(dat_cas_child$study, levels = c("Yang et al.(2019)",
"Niu et al.(2020)",
"Gastine et
al.(2022)"))
# change the label names
labelname2 <- c( "Yang et al.(2019)" = "Yang(2019)",
"Niu et al.(2020)" = "Niu(2020)",
"Gastine et al.(2022)" = "Gastine(2022)")
pl3 <- dat_cas_child %>%
mutate(lowconc=lowconc/20,
medconc=medconc/20,
highconc=highconc/20)%>%
ggplot(mapping=aes(x=tald, y=medconc)) +
geom_line(size=1.5, color="#003B8E") +
geom_ribbon(aes(x=tald,ymin=lowconc,ymax=highconc), fill = "#003B8E",alpha=0.2) +
theme_bw(base_size = 30) +
facet_wrap(~study, ncol = 3,
labeller = labeller(study=as_labeller(labelname2)),
scales="free") +
scale_x_continuous("Time (h)", limits = c(0,24.1), breaks = c(0,4,8,12,16,20,24)) +
scale_y_continuous("Concentration (mg/L/kg)") +
coord_cartesian(ylim = c(0,2.5)) +
ggtitle("b Children: 110cm,20 kg,6-year-old") +
theme (legend.position = "none",
plot.background = element_rect(fill = 'white'),
panel.grid.minor = element_blank(),
panel.grid.major = element_blank(),
plot.title = element_text(hjust = 0,
size = 30),
strip.background = element_rect(fill = "#CCD8E8"))
#export picture
jpeg(filename = paste0(output_dir, "/Caspofungin_Child_plot_ref2.jpg"), width=9000,
height=4000, res=300)
print(pl3)
dev.off()
#-----------------------------------------
#-----Infants 10KG 1Y---------------------
#-----------------------------------------
# 13----Niu et al.(2020)------
# Define the 1-comp model,model info
# TVCL(L/h) =0.14(8.50%)
# TVVd(L) =1.36(11.8 %)
# CL(L/h) =0.14*(BSA/0.79)^0.89*(InAST/3.38)^（-0.23）
# Vd(L) =1.36*(BSA/0.79)
# IIV(CL) =33.3%
# IIV(Vd) =32.9%
# prop error=0.266
# Typical population:
# Infants With Allogeneic Hematopoietic Stem Cell Transplantation
# age : 1 years old
# BSA = (WT*HT/3600)^0.5
# BSA : 0.441 m^2
# BW : 10kg
# Height: 70cm
# Dose: 70 mg/m^2 on day 1,followed by 50 mg/m^2 QD,Infusion for 1h
set.seed(1234567898)
# 1-comp model
mod13 <- RxODE({
CL =TVCL*exp(iiv.CL); #a variable in the model.
Vd =TVVd*exp(iiv.Vd);
conc=centr/Vd;
d/dt(centr)=-CL*conc;#central
cp=conc*(1+prop.err.sd)#RUV
})
# Adults
# Define typical patient:
# Children With Allogeneic Hematopoietic Stem Cell Transplantation
# Age : 10 years old
# BW : 30kg
# BSA : 0.79 m^2
# InAST: 3.38
BSA <- 0.441
InAST<- 3.38
# Define fixed effect parameters
theta13<- c(TVCL =0.14*(BSA/0.79)^0.89*(InAST/3.38)^(-0.23),
TVVd =1.36*(BSA/0.79))
# Define between subject variability
omega13 <- lotri(iiv.CL ~ 0.333^2, iiv.Vd ~ 0.329^2)
# Define unexplained variability
sigma13 <- lotri(prop.err.sd ~ 0.266^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70*BSA # mg 1-h infusion
dose_cas_later<-50*BSA # mg 1-h infusion
# Define event record
ev13 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim13 <- rxSolve(mod13,theta13,ev13,omega=omega13,sigma=sigma13,nSub=1000)
# Concentration-Time plot
pk_CAS13 <- sim13 %>%
group_by(time) %>%
# 10-90% Prediction interval
summarise(medCL = median(CL),
medconc = median(cp),
lowconc = quantile(cp,0.1),
highconc = quantile(cp, 0.9)) %>%
ungroup() %>%
# time after last dose
mutate(time = as.numeric(time),
tald = time-72)
dat13 <- pk_CAS13 %>%
mutate(study="Niu et al.(2020)",
drug="CAS",
pop="Infant")
# 14----Gastine et al.(2022)-----
# Define the 2-comp model,model info
# CL(L/h/70kg) = 0.790
# V1(L/70kg) = 7.75
# Q(L/h/70kg) = 1.2
# V2(L/70kg) = 5.29
# IIV(CL) = 0.275(12.0%)
# IIV(V1) = 0.315(21.7%)
# IIV(V2) = 0.151(70.3%)
# Proportional error=0.194
# Typical population:
# Children paediatric patients
# age : 1 years old
# BW : 10kg
# BSA : 0.441m^2
# Dose: 70 mg/m^2 on day 1,followed by 50 mg/m^2 QD,Infusion for 1h
set.seed(123456789)
# 2-comp model
mod14 <- RxODE({
CL = TVCL*exp(iiv.CL );
V1 = TVV1*exp(iiv.V1);
Q = TVQ;
V2 = TVV2*exp(iiv.V2);
C1 = centr/V1;
C2 = peri/V2;
d/dt(centr) = - CL*C1 - Q*C1 + Q*C2;
d/dt(peri) = Q*C1 - Q*C2;
cp = C1*(1 + prop.err.sd)
})
# Define typical patient:
# children
# BW :30 kg
BW <- 10
BSA<- 0.441
# Define fixed effect parameters
theta14<- c(TVCL =0.79*BW/70,
TVV1 =7.75*BW/70,
TVQ =1.2*BW/70,
TVV2 =5.29*BW/70)
# Define between subject variability
omega14 <- lotri(iiv.CL ~ 0.275^2,
iiv.V1 ~ 0.315^2,
iiv.V2 ~ 0.151^2)
# Define unexplained variability
sigma14 <- lotri(prop.err.sd ~ 0.194^2)
# DOSE of CAS(iv)
dose_cas_day1 <-70*BSA # mg 1-h infusion
dose_cas_later<-50*BSA # mg 1-h infusion
# Define event record
ev14 <- et(amountUnits="mg", timeUnits="hours") %>%
add.dosing(dosing.to = "centr",dose = dose_cas_day1, rate = dose_cas_day1/1,
nbr.doses = 1, start.time = 0) %>%
add.dosing(dosing.to = "centr",dose = dose_cas_later, rate = dose_cas_later/1,
nbr.doses = 3, dosing.interval = 24,start.time = 24) %>%
# sampling:0-24h after the last dosing
add.sampling(seq(from=72,to=96,by=1))
# Perform simulation
# total number of subject: 1000
sim14 <- rxSolve(mod14,theta14,ev14,omega=omega14,sigma=sigma14,nSub=1000)
